| Year |
Citation |
Score |
| 2023 |
Vaidya H, Jeong HS, Keith K, Maegawa S, Calendo G, Madzo J, Jelinek J, Issa JJ. Author Correction: DNA methylation entropy as a measure of stem cell replication and aging. Genome Biology. 24: 104. PMID 37122020 DOI: 10.1186/s13059-023-02943-8 |
0.311 |
|
| 2023 |
Vaidya H, Jeong HS, Keith K, Maegawa S, Calendo G, Madzo J, Jelinek J, Issa JJ. DNA methylation entropy as a measure of stem cell replication and aging. Genome Biology. 24: 27. PMID 36797759 DOI: 10.1186/s13059-023-02866-4 |
0.361 |
|
| 2023 |
Tricarico R, Madzo J, Scher G, Cohen M, Jelinek J, Maegawa S, Nagarathinam R, Scher C, Chang WC, Nicolas E, Slifker M, Zhou Y, Devarajan K, Cai KQ, Kwok T, ... ... Issa JP, et al. TET1 and TDG suppress inflammatory response in intestinal tumorigenesis: implications for colorectal tumors with the CpG Island Methylator Phenotype. Gastroenterology. PMID 36764492 DOI: 10.1053/j.gastro.2023.01.039 |
0.377 |
|
| 2023 |
Kim JY, Jelinek J, Lee YH, Kim DH, Kang K, Ryu SH, Moon HR, Cho K, Rha SH, Cha JK, Issa JJ, Kim J. Hypomethylation in MTNR1B: a novel epigenetic marker for atherosclerosis profiling using stenosis radiophenotype and blood inflammatory cells. Clinical Epigenetics. 15: 11. PMID 36658621 DOI: 10.1186/s13148-023-01423-x |
0.341 |
|
| 2022 |
Sun A, Park P, Cole L, Vaidya H, Maegawa S, Keith K, Calendo G, Madzo J, Jelinek J, Jobin C, Issa JJ. Non-pathogenic microbiota accelerate age-related CpG Island methylation in colonic mucosa. Epigenetics. 1-14. PMID 36572998 DOI: 10.1080/15592294.2022.2160568 |
0.375 |
|
| 2022 |
Ghosh J, Schultz BM, Chan J, Wultsch C, Singh R, Shureiqi I, Chow S, Doymaz A, Varriano S, Driscoll M, Muse J, Kleiman FE, Krampis K, Issa JJ, Sapienza C. Epigenome-Wide Study Identifies Epigenetic Outliers in Normal Mucosa of Patients with Colorectal Cancer. Cancer Prevention Research (Philadelphia, Pa.). OF1-OF12. PMID 36219239 DOI: 10.1158/1940-6207.CAPR-22-0258 |
0.354 |
|
| 2022 |
Pandey S, Djibo R, Darracq A, Calendo G, Zhang H, Henry RA, Andrews AJ, Baylin SB, Madzo J, Najmanovich R, Issa JJ, Raynal NJ. Selective CDK9 Inhibition by Natural Compound Toyocamycin in Cancer Cells. Cancers. 14. PMID 35884401 DOI: 10.3390/cancers14143340 |
0.358 |
|
| 2022 |
Issa JP. The Two-Hit Hypothesis Meets Epigenetics. Cancer Research. 82: 1167-1169. PMID 35373289 DOI: 10.1158/0008-5472.CAN-22-0405 |
0.456 |
|
| 2021 |
Panjarian S, Issa JJ. The Roles of DNA Demethylases in Triple-Negative Breast Cancer. Pharmaceuticals (Basel, Switzerland). 14. PMID 34209564 DOI: 10.3390/ph14070628 |
0.363 |
|
| 2021 |
Panjarian S, Madzo J, Keith K, Slater CM, Sapienza C, Jelinek J, Issa JJ. Accelerated aging in normal breast tissue of women with breast cancer. Breast Cancer Research : Bcr. 23: 58. PMID 34022936 DOI: 10.1186/s13058-021-01434-7 |
0.312 |
|
| 2021 |
Hu X, Estecio MR, Chen R, Reuben A, Wang L, Fujimoto J, Carrot-Zhang J, McGranahan N, Ying L, Fukuoka J, Chow CW, Pham HHN, Godoy MCB, Carter BW, Behrens C, ... ... Issa JJ, et al. Evolution of DNA methylome from precancerous lesions to invasive lung adenocarcinomas. Nature Communications. 12: 687. PMID 33514726 DOI: 10.1038/s41467-021-20907-z |
0.3 |
|
| 2021 |
Xu J, Shi J, Cui X, Cui Y, Li JJ, Goel A, Chen X, Issa JP, Su J, Li W. Cellular Heterogeneity-Adjusted cLonal Methylation (CHALM) improves prediction of gene expression. Nature Communications. 12: 400. PMID 33452255 DOI: 10.1038/s41467-020-20492-7 |
0.45 |
|
| 2020 |
Kim JY, Choi BG, Jelinek J, Kim DH, Lee SH, Cho K, Rha SH, Lee YH, Jin HS, Choi DK, Kim GE, Kwon SU, Hwang J, Cha JK, Lee S, ... Issa JJ, et al. Promoter methylation changes in ALOX12 and AIRE1: novel epigenetic markers for atherosclerosis. Clinical Epigenetics. 12: 66. PMID 32398127 DOI: 10.1186/S13148-020-00846-0 |
0.371 |
|
| 2019 |
Majewski T, Yao H, Bondaruk J, Chung W, Lee S, Lee JG, Zhang S, Cogdell D, Yang G, Choi W, Dinney C, Grossman HB, Logothetis C, Scherer SE, Guo CC, ... ... Issa JP, et al. Whole-Organ Genomic Characterization of Mucosal Field Effects Initiating Bladder Carcinogenesis. Cell Reports. 26: 2241-2256.e4. PMID 30784602 DOI: 10.1016/j.celrep.2019.01.095 |
0.33 |
|
| 2019 |
Tao Y, Kang B, Petkovich DA, Bhandari YR, In J, Stein-O'Brien G, Kong X, Xie W, Zachos N, Maegawa S, Vaidya H, Brown S, Chiu Yen RW, Shao X, Thakor J, ... ... Issa JP, et al. Aging-like Spontaneous Epigenetic Silencing Facilitates Wnt Activation, Stemness, and Braf-Induced Tumorigenesis. Cancer Cell. 35: 315-328.e6. PMID 30753828 DOI: 10.1016/J.Ccell.2019.01.005 |
0.333 |
|
| 2019 |
Kim JY, Jelinek J, Hwang J, Shin JW, Jeong HS, Choi BG, Issa J, Kim J. Abstract WP551: Senescence-Induced Methylation Changes in Global DNA and Atherosclerosis-Related Genes in Human Vascular Endothelial Cells Stroke. 50. DOI: 10.1161/Str.50.Suppl_1.Wp551 |
0.431 |
|
| 2018 |
Zhang H, Pandey S, Travers M, Sun H, Morton G, Madzo J, Chung W, Khowsathit J, Perez-Leal O, Barrero CA, Merali C, Okamoto Y, Sato T, Pan J, Garriga J, ... ... Issa JJ, et al. Targeting CDK9 Reactivates Epigenetically Silenced Genes in Cancer. Cell. 175: 1244-1258.e26. PMID 30454645 DOI: 10.1016/J.Cell.2018.09.051 |
0.335 |
|
| 2018 |
Good CR, Panjarian S, Kelly AD, Madzo J, Patel B, Jelinek J, Issa JJ. TET1-mediated hypomethylation activates oncogenic signaling in triple-negative breast cancer. Cancer Research. PMID 29891505 DOI: 10.1158/0008-5472.Can-17-2082 |
0.361 |
|
| 2018 |
Garriga J, Laumet G, Chen SR, Zhang Y, Madzo J, Issa JJ, Pan HL, Jelinek J. Nerve injury-induced chronic pain is associated with persistent DNA methylation reprogramming in dorsal root ganglion. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. PMID 29875269 DOI: 10.1523/JNEUROSCI.2616-17.2018 |
0.305 |
|
| 2018 |
Kelly AD, Madzo J, Madireddi P, Kropf P, Good CR, Jelinek J, Issa JJ. Demethylator phenotypes in acute myeloid leukemia. Leukemia. PMID 29556023 DOI: 10.1038/s41375-018-0084-2 |
0.304 |
|
| 2018 |
Jelinek J, Lee JT, Cesaroni M, Madzo J, Liang S, Lu Y, Issa JJ. Digital Restriction Enzyme Analysis of Methylation (DREAM). Methods in Molecular Biology (Clifton, N.J.). 1708: 247-265. PMID 29224148 DOI: 10.1007/978-1-4939-7481-8_13 |
0.313 |
|
| 2018 |
Kim J, Jelinek J, Hwang J, Shin JW, Jeong HS, Lee YH, Issa J, Kim J. Abstract WMP73:
Adck5, Mtnr1b
And
Kndc1
: Atherosclerosis-related Epigenetic Biomarkers Identified From Peripheral Leukocytes of Atherosclerotic Patients Stroke. 49. DOI: 10.1161/Str.49.Suppl_1.Wmp73 |
0.32 |
|
| 2018 |
Pandey S, Zhang H, Barrero CA, Merali S, Graña X, Issa J. Abstract 2995: CDK9 phosphorylates BRG1 chromatin remodeler Cancer Research. 78: 2995-2995. DOI: 10.1158/1538-7445.Am2018-2995 |
0.342 |
|
| 2017 |
Werner RJ, Kelly AD, Issa JJ. Epigenetics and Precision Oncology. Cancer Journal (Sudbury, Mass.). 23: 262-269. PMID 28926426 DOI: 10.1097/PPO.0000000000000281 |
0.417 |
|
| 2017 |
Maegawa S, Lu Y, Tahara T, Lee JT, Madzo J, Liang S, Jelinek J, Colman RJ, Issa JJ. Caloric restriction delays age-related methylation drift. Nature Communications. 8: 539. PMID 28912502 DOI: 10.1038/S41467-017-00607-3 |
0.314 |
|
| 2017 |
Good CR, Madzo J, Patel B, Maegawa S, Engel N, Jelinek J, Issa JJ. A novel isoform of TET1 that lacks a CXXC domain is overexpressed in cancer. Nucleic Acids Research. PMID 28531272 DOI: 10.1093/Nar/Gkx435 |
0.412 |
|
| 2017 |
Kelly AD, Issa JJ. The promise of epigenetic therapy: reprogramming the cancer epigenome. Current Opinion in Genetics & Development. 42: 68-77. PMID 28412585 DOI: 10.1016/j.gde.2017.03.015 |
0.425 |
|
| 2017 |
Sato T, Issa JJ, Kropf P. DNA Hypomethylating Drugs in Cancer Therapy. Cold Spring Harbor Perspectives in Medicine. PMID 28159832 DOI: 10.1101/cshperspect.a026948 |
0.434 |
|
| 2017 |
Issa J. Abstract IA15: Multiple targetable pathways for epigenetic therapy Cancer Research. 77. DOI: 10.1158/1538-7445.Newfront17-Ia15 |
0.474 |
|
| 2017 |
Deliard S, Okamoto Y, Madzo J, Jelinek J, Issa J. Abstract LB-100: Potential role of the splicing factor SF3B1 in epigenetic regulation Cancer Research. 77. DOI: 10.1158/1538-7445.Am2017-Lb-100 |
0.507 |
|
| 2017 |
Good CR, Kelly A, Madzo J, Jelinek J, Issa J. Abstract 3359: TET1 mediated hypomethylation activates oncogenic signaling pathways in triple negative breast cancer Cancer Research. 77: 3359-3359. DOI: 10.1158/1538-7445.Am2017-3359 |
0.467 |
|
| 2016 |
Raynal NJ, Da Costa EM, Lee JT, Gharibyan V, Ahmed S, Zhang H, Sato T, Malouf GG, Issa JJ. REPOSITIONING FDA-APPROVED DRUGS IN COMBINATION WITH EPIGENETIC DRUGS TO REPROGRAM COLON CANCER EPIGENOME. Molecular Cancer Therapeutics. PMID 27980103 DOI: 10.1158/1535-7163.MCT-16-0588 |
0.334 |
|
| 2016 |
Sato T, Cesaroni M, Chung W, Panjarian S, Tran A, Madzo J, Okamoto Y, Zhang H, Chen X, Jelinek J, Issa JJ. Transcriptional Selectivity of Epigenetic Therapy in Cancer. Cancer Research. PMID 27879268 DOI: 10.1158/0008-5472.Can-16-0834 |
0.45 |
|
| 2016 |
Jones PA, Issa JJ, Baylin S. Targeting the cancer epigenome for therapy. Nature Reviews. Genetics. 17: 630-641. PMID 27629931 DOI: 10.1038/Nrg.2016.93 |
0.316 |
|
| 2016 |
Overman MJ, Morris V, Moinova H, Manyam G, Ensor J, Lee MS, Eng C, Kee B, Fogelman D, Shroff RT, LaFramboise T, Mazard T, Feng T, Hamilton S, Broom B, ... ... Issa JP, et al. Phase I/II study of azacitidine and capecitabine/oxaliplatin (CAPOX) in refractory CIMP-high metastatic colorectal cancer: evaluation of circulating methylated vimentin. Oncotarget. PMID 27542211 DOI: 10.18632/Oncotarget.11317 |
0.324 |
|
| 2016 |
Sapienza C, Issa JP. Diet, Nutrition, and Cancer Epigenetics. Annual Review of Nutrition. PMID 27022771 DOI: 10.1146/Annurev-Nutr-121415-112634 |
0.351 |
|
| 2016 |
Kleb B, Estécio MR, Zhang J, Tzelepi V, Chung W, Jelinek J, Navone NM, Tahir S, Marquez VE, Issa JP, Maity S, Aparicio A. Differentially methylated genes and androgen receptor re-expression in small cell prostate carcinomas. Epigenetics. 0. PMID 26890396 DOI: 10.1080/15592294.2016.1146851 |
0.358 |
|
| 2016 |
Yamazaki J, Taby R, Jelinek J, Raynal NJ, Cesaroni M, Pierce SA, Kornblau SM, Bueso-Ramos CE, Ravandi F, Kantarjian HM, Issa JP. Hypomethylation of TET2 Target Genes Identifies a Curable Subset of Acute Myeloid Leukemia. Journal of the National Cancer Institute. 108. PMID 26568194 DOI: 10.1093/jnci/djv323 |
0.375 |
|
| 2016 |
Sato T, Cesaroni M, Tran A, Madzo J, Okamoto Y, Zhang H, Panjarian S, Jelinek J, Issa J. Abstract B42: Decitabine specifically targets genes that gain DNA methylation and lose expression in cancer and can be combined with histone methylation inhibitors for increased efficacy Cancer Research. 76. DOI: 10.1158/1538-7445.Chromepi15-B42 |
0.556 |
|
| 2016 |
madireddi p, Jelinek J, Lee J, Sato T, Issa J. Abstract 4442: Very low methylation is a novel epigenetic regulatory mechanism in normal tissues and predisposes to hypermethylation in cancer Cancer Research. 76: 4442-4442. DOI: 10.1158/1538-7445.Am2016-4442 |
0.565 |
|
| 2016 |
Sun A, Jelinek J, Maegawa S, Jobin C, Issa J. Abstract 4441: Non-pathogenic bacteria change host DNA methylationin vivo Cancer Research. 76: 4441-4441. DOI: 10.1158/1538-7445.Am2016-4441 |
0.445 |
|
| 2016 |
Kang B, In J, Zachos N, Huso D, Maegawa S, Issa J, Easwaran H, Baylin SB. Abstract 4273: Oncogenic BRAFV600E drives stem cell niche factors-independent growth and tumorigenic transformation in colon organoids Cancer Research. 76: 4273-4273. DOI: 10.1158/1538-7445.Am2016-4273 |
0.413 |
|
| 2016 |
Good CR, Madzo J, Maegawa S, Engel N, Jelinek J, Issa J. Abstract 2659: A novel isoform of TET1 that lacks a CXXC domain is overexpressed in cancer Cancer Research. 76: 2659-2659. DOI: 10.1158/1538-7445.Am2016-2659 |
0.526 |
|
| 2015 |
Raynal NJ, Lee JT, Wang Y, Beaudry A, Madireddi P, Garriga J, Malouf GG, Dumont S, Dettman EJ, Gharibyan V, Ahmed S, Chung W, Childers WE, Abou-Gharbia M, Henry RA, ... ... Issa JJ, et al. Targeting calcium signaling induces epigenetic reactivation of tumor suppressor genes in cancer. Cancer Research. PMID 26719529 DOI: 10.1158/0008-5472.Can-14-2391 |
0.384 |
|
| 2015 |
Bouwmeester MC, Ruiter S, Lommelaars T, Sippel J, Hodemaekers HM, van den Brandhof EJ, Pennings JL, Kamstra JH, Jelinek J, Issa JJ, Legler J, van der Ven LT. Zebrafish embryos as a screen for DNA methylation modifications after compound exposure. Toxicology and Applied Pharmacology. 291: 84-96. PMID 26712470 DOI: 10.1016/j.taap.2015.12.012 |
0.343 |
|
| 2015 |
Jin C, Qin T, Barton MC, Jelinek J, Issa JJ. Minimal Role of Base Excision Repair in TET-Induced Global DNA Demethylation in HEK293T Cells. Epigenetics. 0. PMID 26440216 DOI: 10.1080/15592294.2015.1091145 |
0.768 |
|
| 2015 |
Qin T, Si J, Raynal NJ, Wang X, Gharibyan V, Ahmed S, Hu X, Jin C, Lu Y, Shu J, Estecio MR, Jelinek J, Issa JP. Epigenetic synergy between decitabine and platinum derivatives. Clinical Epigenetics. 7: 97. PMID 26366234 DOI: 10.1186/S13148-015-0131-Z |
0.793 |
|
| 2015 |
Foy JP, Pickering CR, Papadimitrakopoulou VA, Jelinek J, Lin SH, William WN, Mitchell FT, Wang J, Lang W, Feng L, Zhang L, Kim ES, Fan YH, Hong WK, El-Naggar A, ... ... Issa JJ, et al. New DNA methylation markers and global DNA hypomethylation are associated with oral cancer development. Cancer Prevention Research (Philadelphia, Pa.). PMID 26342026 DOI: 10.1158/1940-6207.Capr-14-0179 |
0.487 |
|
| 2015 |
Malouf GG, Tahara T, Paradis V, Fabre M, Guettier C, Yamazaki J, Long H, Lu Y, Raynal NJ, Jelinek J, Mouawad R, Khayat D, Brugières L, Raymond E, Issa JP. Methylome sequencing for fibrolamellar hepatocellular carcinoma depicts distinctive features. Epigenetics. 10: 872-81. PMID 26224146 DOI: 10.1080/15592294.2015.1076955 |
0.427 |
|
| 2015 |
Fujii S, Srivastava V, Hegde A, Kondo Y, Shen L, Hoshino K, Gonzalez Y, Wang J, Sasai K, Ma X, Katayama H, Estecio MR, Hamilton SR, Wistuba I, Issa JP, et al. Regulation of AURKC expression by CpG island methylation in human cancer cells. Tumour Biology : the Journal of the International Society For Oncodevelopmental Biology and Medicine. PMID 25990457 DOI: 10.1007/s13277-015-3553-5 |
0.432 |
|
| 2015 |
Yamazaki J, Jelinek J, Lu Y, Cesaroni M, Madzo J, Neumann F, He R, Taby R, Vasanthakumar A, Macrae T, Ostler KR, Kantarjian HM, Liang S, Estecio MR, Godley LA, ... Issa JP, et al. TET2 mutations affect non-CpG island DNA methylation at enhancers and transcription factor binding sites in chronic myelomonocytic leukemia. Cancer Research. PMID 25972343 DOI: 10.1158/0008-5472.Can-14-0739 |
0.389 |
|
| 2015 |
Tsimberidou AM, Said R, Culotta K, Wistuba I, Jelinek J, Fu S, Falchook G, Naing A, Piha-Paul S, Zinner R, Siddik ZH, He G, Hess K, Stewart DJ, Kurzrock R, ... Issa JP, et al. Phase I study of azacitidine and oxaliplatin in patients with advanced cancers that have relapsed or are refractory to any platinum therapy. Clinical Epigenetics. 7: 29. PMID 25806091 DOI: 10.1186/S13148-015-0065-5 |
0.339 |
|
| 2015 |
Kropf PL, Pancari PA, Fung H, Kantarjian HM, Xiao L, Xuelin H, Issa J. Superior Response Rates for Patients with Myeloid Malignancies Treated with the Combination of Decitabine (DAC) and Arsenic Trioxide (ATO) in a Phase II Adaptive Three Arm Randomization Study: DAC +/- Carboplatin or ATO Blood. 126: 3775-3775. DOI: 10.1182/Blood.V126.23.3775.3775 |
0.32 |
|
| 2015 |
Gottipati S, Rohatagi S, Chung W, Taverna P, Kantarjian HM, Roboz GJ, Kropf PL, Azab M, Issa J. Multivariate Analysis Identifies Significant Correlations Between Baseline Biomarkers, DNA Demethylation and Clinical Responses in 122 Patients Treated in a Phase 1/2, Study of Guadecitabine (SGI-110), in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia (r/r AML) Blood. 126: 2594-2594. DOI: 10.1182/Blood.V126.23.2594.2594 |
0.401 |
|
| 2015 |
Sato T, Cesaroni M, Jelinek J, Issa J. Abstract 3521: Combined targeting of DNA and histone methylation improves the efficacy and specificity of epigenetic therapy Cancer Research. 75: 3521-3521. DOI: 10.1158/1538-7445.Am2015-3521 |
0.531 |
|
| 2015 |
Madireddi P, Jelinek J, Lee J, Cesaroni M, Rodrigues R, Zhang Y, Issa J. Abstract 2954: Low level methylation (1-20%) or methylation seeds is a distinct epigenetic regulator of gene expression and is a strong predictor of methylation gains in AML and MDS patients Cancer Research. 75: 2954-2954. DOI: 10.1158/1538-7445.Am2015-2954 |
0.546 |
|
| 2015 |
Sun A, Cesaroni M, Jobin C, Barrero C, Jelinek J, Sautter JD, Rams TE, Merali S, Issa J. Abstract 2889: Distinct microbiome in colorectal cancers with the CpG Island Methylator Phenotype Cancer Research. 75: 2889-2889. DOI: 10.1158/1538-7445.Am2015-2889 |
0.383 |
|
| 2015 |
Panjarian SB, Slater C, Madzo J, Jelinek J, Chen X, Issa J. Abstract 1071: Age-dependent DNA methylation in normal breast epithelium and breast cancer Cancer Research. 75: 1071-1071. DOI: 10.1158/1538-7445.Am2015-1071 |
0.512 |
|
| 2014 |
Cui Y, Hausheer F, Beaty R, Zahnow C, Issa JP, Bunz F, Baylin SB. A recombinant reporter system for monitoring reactivation of an endogenously DNA hypermethylated gene. Cancer Research. 74: 3834-43. PMID 24876104 DOI: 10.1158/0008-5472.Can-13-2287 |
0.484 |
|
| 2014 |
Jin C, Lu Y, Jelinek J, Liang S, Estecio MR, Barton MC, Issa JP. TET1 is a maintenance DNA demethylase that prevents methylation spreading in differentiated cells. Nucleic Acids Research. 42: 6956-71. PMID 24875481 DOI: 10.1093/Nar/Gku372 |
0.453 |
|
| 2014 |
Pathiraja TN, Nayak SR, Xi Y, Jiang S, Garee JP, Edwards DP, Lee AV, Chen J, Shea MJ, Santen RJ, Gannon F, Kangaspeska S, Jelinek J, Issa JP, Richer JK, et al. Epigenetic reprogramming of HOXC10 in endocrine-resistant breast cancer. Science Translational Medicine. 6: 229ra41. PMID 24670685 DOI: 10.1126/Scitranslmed.3008326 |
0.418 |
|
| 2014 |
Maegawa S, Gough SM, Watanabe-Okochi N, Lu Y, Zhang N, Castoro RJ, Estecio MR, Jelinek J, Liang S, Kitamura T, Aplan PD, Issa JP. Age-related epigenetic drift in the pathogenesis of MDS and AML. Genome Research. 24: 580-91. PMID 24414704 DOI: 10.1101/Gr.157529.113 |
0.418 |
|
| 2014 |
Tahara T, Yamamoto E, Madireddi P, Suzuki H, Maruyama R, Chung W, Garriga J, Jelinek J, Yamano HO, Sugai T, Kondo Y, Toyota M, Issa JP, Estécio MR. Colorectal carcinomas with CpG island methylator phenotype 1 frequently contain mutations in chromatin regulators. Gastroenterology. 146: 530-38.e5. PMID 24211491 DOI: 10.1053/j.gastro.2013.10.060 |
0.338 |
|
| 2014 |
Okamoto Y, Shinjo K, Shimizu Y, Sano T, Yamao K, Gao W, Fujii M, Osada H, Sekido Y, Murakami S, Tanaka Y, Joh T, Sato S, Takahashi S, Wakita T, ... ... Issa JP, et al. Hepatitis virus infection affects DNA methylation in mice with humanized livers. Gastroenterology. 146: 562-72. PMID 24184133 DOI: 10.1053/j.gastro.2013.10.056 |
0.334 |
|
| 2014 |
Garcia-Manero G, Ritchie EK, Walsh K, Savona M, Kropf P, O'Connell C, Tibes R, Daver NG, Jabbour E, Lunin S, Rosenblat TL, Yee K, Stock W, Griffiths EA, Mace JR, ... ... Issa J, et al. First Clinical Results of a Randomized Phase 2 Dose-Response Study of SGI-110, a Novel Subcutaneous (SC) Hypomethylating Agent (HMA), in 102 Patients with Intermediate (Int) or High Risk (HR) Myelodysplastic Syndromes (MDS) or Chronic Myelomonocytic Leukemia (CMML) Blood. 124: 529-529. DOI: 10.1182/Blood.V124.21.529.529 |
0.318 |
|
| 2014 |
Kim SJ, Swierczek S, Song J, Issa J, Jelinek J, Prchal JT. Focal Reactivation of X-Chromosome in Female Patients with PV and ET Blood. 124: 3225-3225. DOI: 10.1182/Blood.V124.21.3225.3225 |
0.364 |
|
| 2014 |
Tsimberidou AM, Culotta K, Wistuba I, Fu S, Naing A, Falchook G, Piha-Paul S, Zinner R, Rodriguez-Canales J, He G, Siddik ZH, Jelinek J, Chung W, Ye Y, Said R, ... ... Issa J, et al. Abstract CT201: Phase I study of 5-azacytidine and oxaliplatin in patients with advanced cancers relapsed or refractory to platinum compounds Cancer Research. 74. DOI: 10.1158/1538-7445.Am2014-Ct201 |
0.373 |
|
| 2014 |
Czerniak BA, Lee S, Bondaruk J, Lee S, Majewski T, Zhang S, Shen L, Liu Y, Guo C, Dinney C, Grossman HB, Zhang W, Bar-Eli M, Baggerly K, Behringer R, ... ... Issa J, et al. Abstract 5256: Mechanism of field cancerization Cancer Research. 74: 5256-5256. DOI: 10.1158/1538-7445.Am2014-5256 |
0.396 |
|
| 2014 |
Zhang H, Raynal NJ, Jacobson MA, Issa J. Abstract 378: Discovering potential epigenetic anti-cancer drugs derived from natural compounds Cancer Research. 74: 378-378. DOI: 10.1158/1538-7445.Am2014-378 |
0.53 |
|
| 2014 |
Okamoto Y, Yamazaki J, Sato T, Cesaroni M, Chung W, Garriga J, Jelinek J, Katz RA, Issa J. Abstract 373: An siRNA screen identifies CHD4 as a target for epigenetic therapy Cancer Research. 74: 373-373. DOI: 10.1158/1538-7445.Am2014-373 |
0.543 |
|
| 2014 |
Stewart DJ, Nunez MI, Jelinek J, Hong D, Gupta S, Aldaz CM, Issa J, Kurzrock R, Wistuba II. Abstract 2303: Decitabine impact on immunohistochemistry scores for tumor suppressor genes FHIT, WWOX, FUS1 and PTEN in human tumor samples Cancer Research. 74: 2303-2303. DOI: 10.1158/1538-7445.Am2014-2303 |
0.405 |
|
| 2013 |
Malouf GG, Taube JH, Lu Y, Roysarkar T, Panjarian S, Estecio MR, Jelinek J, Yamazaki J, Raynal NJ, Long H, Tahara T, Tinnirello A, Ramachandran P, Zhang XY, Liang S, ... ... Issa JP, et al. Architecture of epigenetic reprogramming following Twist1-mediated epithelial-mesenchymal transition. Genome Biology. 14: R144. PMID 24367927 DOI: 10.1186/Gb-2013-14-12-R144 |
0.37 |
|
| 2013 |
Tahara T, Maegawa S, Chung W, Garriga J, Jelinek J, Estécio MR, Shibata T, Hirata I, Arisawa T, Issa JP. Examination of whole blood DNA methylation as a potential risk marker for gastric cancer. Cancer Prevention Research (Philadelphia, Pa.). 6: 1093-100. PMID 23943784 DOI: 10.1158/1940-6207.CAPR-13-0034 |
0.373 |
|
| 2013 |
Yamazaki J, Estecio MR, Lu Y, Long H, Malouf GG, Graber D, Huo Y, Ramagli L, Liang S, Kornblau SM, Jelinek J, Issa JP. The epigenome of AML stem and progenitor cells. Epigenetics. 8: 92-104. PMID 23249680 DOI: 10.4161/Epi.23243 |
0.368 |
|
| 2013 |
Kantarjian HM, Jabbour E, Yee K, Kropf P, O'Connell C, Stock W, Tibes R, Rizzieri D, Walsh K, Griffiths EA, Roboz GJ, Savona M, Ervin T, Podoltsev NA, Pemmaraju N, ... ... Issa J, et al. First Clinical Results Of a Randomized Phase 2 Study Of SGI-110, a Novel Subcutaneous (SQ) Hypomethylating Agent (HMA), In Adult Patients With Acute Myeloid Leukemia (AML) Blood. 122: 497-497. DOI: 10.1182/Blood.V122.21.497.497 |
0.31 |
|
| 2013 |
Chung W, Taverna P, Lyons JF, Hao Y, Azab M, Kantarjian HM, Kropf P, Issa J. Determinants Of Demethylation and Clinical Response In AML Patients Treated With SGI-110, a Novel Subcutaneous (SQ) Hypomethylating Agent (HMA) In a Phase 1 Study Blood. 122: 1442-1442. DOI: 10.1182/Blood.V122.21.1442.1442 |
0.417 |
|
| 2013 |
Issa J. Abstract ED02-01: Epigenetic variation as the missing link between aging and cancer Cancer Prevention Research. 6. DOI: 10.1158/1940-6215.Prev-13-Ed02-01 |
0.509 |
|
| 2013 |
Malouf GG, Su X, Yao H, Wood CG, Lu Y, Liang S, Thompson EJ, Doss DJ, Jelinek J, Issa J, Tannir NM. Abstract 2980: Integrated transcriptome and methylome sequencing of Xp11 translocation renal cell carcinomas reveal uncoupling of DNA methylation and transcriptional profiles. Cancer Research. 73: 2980-2980. DOI: 10.1158/1538-7445.Am2013-2980 |
0.525 |
|
| 2012 |
Overman MJ, Eng C, Kee BK, Fogelman DR, Fark C, Hippert R, Holter S, Issa JP, Hamilton SR, Kopetz S. A phase I/II study of azacitidine and capecitabine/oxaliplatin (CAPOX) in refractory metastatic colorectal cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 30: 450. PMID 27983228 DOI: 10.1200/Jco.2012.30.4_Suppl.450 |
0.399 |
|
| 2012 |
Jelinek J, Liang S, Lu Y, He R, Ramagli LS, Shpall EJ, Estecio MR, Issa JP. Conserved DNA methylation patterns in healthy blood cells and extensive changes in leukemia measured by a new quantitative technique. Epigenetics. 7: 1368-78. PMID 23075513 DOI: 10.4161/Epi.22552 |
0.444 |
|
| 2012 |
Estécio MR, Gallegos J, Dekmezian M, Lu Y, Liang S, Issa JP. SINE retrotransposons cause epigenetic reprogramming of adjacent gene promoters. Molecular Cancer Research : McR. 10: 1332-42. PMID 22952045 DOI: 10.1158/1541-7786.MCR-12-0351 |
0.477 |
|
| 2012 |
Ulrich CM, Toriola AT, Koepl LM, Sandifer T, Poole EM, Duggan C, McTiernan A, Issa JP. Metabolic, hormonal and immunological associations with global DNA methylation among postmenopausal women. Epigenetics. 7: 1020-8. PMID 22869041 DOI: 10.4161/Epi.21464 |
0.366 |
|
| 2012 |
Xu J, Shetty PB, Feng W, Chenault C, Bast RC, Issa JP, Hilsenbeck SG, Yu Y. Methylation of HIN-1, RASSF1A, RIL and CDH13 in breast cancer is associated with clinical characteristics, but only RASSF1A methylation is associated with outcome. Bmc Cancer. 12: 243. PMID 22695491 DOI: 10.1186/1471-2407-12-243 |
0.317 |
|
| 2012 |
Boumber Y, Kantarjian H, Jorgensen J, Wen S, Faderl S, Castoro R, Autry J, Garcia-Manero G, Borthakur G, Jabbour E, Estrov Z, Cortes J, Issa JP, Ravandi F. A randomized study of decitabine versus conventional care for maintenance therapy in patients with acute myeloid leukemia in complete remission. Leukemia. 26: 2428-31. PMID 22665218 DOI: 10.1038/Leu.2012.153 |
0.613 |
|
| 2012 |
Zhang Y, Shu J, Si J, Shen L, Estecio MR, Issa JP. Repetitive elements and enforced transcriptional repression co-operate to enhance DNA methylation spreading into a promoter CpG-island. Nucleic Acids Research. 40: 7257-68. PMID 22600741 DOI: 10.1093/Nar/Gks429 |
0.812 |
|
| 2012 |
Issa JP. DNA methylation as a clinical marker in oncology. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 30: 2566-8. PMID 22564986 DOI: 10.1200/Jco.2012.42.1016 |
0.573 |
|
| 2012 |
Tsai HC, Li H, Van Neste L, Cai Y, Robert C, Rassool FV, Shin JJ, Harbom KM, Beaty R, Pappou E, Harris J, Yen RW, Ahuja N, Brock MV, Stearns V, ... ... Issa JP, et al. Transient low doses of DNA-demethylating agents exert durable antitumor effects on hematological and epithelial tumor cells. Cancer Cell. 21: 430-46. PMID 22439938 DOI: 10.1016/J.Ccr.2011.12.029 |
0.409 |
|
| 2012 |
Yamazaki J, Taby R, Vasanthakumar A, Macrae T, Ostler KR, Shen L, Kantarjian HM, Estecio MR, Jelinek J, Godley LA, Issa JP. Effects of TET2 mutations on DNA methylation in chronic myelomonocytic leukemia. Epigenetics. 7: 201-7. PMID 22395470 DOI: 10.4161/Epi.7.2.19015 |
0.379 |
|
| 2012 |
Bhardwaj A, Song HW, Beildeck M, Kerkhofs S, Castoro R, Shanker S, De Gendt K, Suzuki K, Claessens F, Issa JP, Orgebin-Crist MC, Wilkinson MF. DNA demethylation-dependent AR recruitment and GATA factors drive Rhox5 homeobox gene transcription in the epididymis. Molecular Endocrinology (Baltimore, Md.). 26: 538-49. PMID 22322598 DOI: 10.1210/Me.2011-1059 |
0.328 |
|
| 2012 |
Raynal NJ, Si J, Taby RF, Gharibyan V, Ahmed S, Jelinek J, Estécio MR, Issa JP. DNA methylation does not stably lock gene expression but instead serves as a molecular mark for gene silencing memory. Cancer Research. 72: 1170-81. PMID 22219169 DOI: 10.1158/0008-5472.Can-11-3248 |
0.833 |
|
| 2012 |
Challen GA, Sun D, Jeong M, Luo M, Jelinek J, Berg JS, Bock C, Vasanthakumar A, Gu H, Xi Y, Liang S, Lu Y, Darlington GJ, Meissner A, Issa JP, et al. Dnmt3a is essential for hematopoietic stem cell differentiation. Nature Genetics. 44: 23-31. PMID 22138693 DOI: 10.1038/Ng.1009 |
0.365 |
|
| 2012 |
Saintigny P, Lang W, Jelinek J, Pickering CR, Feng L, Frederick MJ, Zhang L, Ren H, Lee JJ, Kim ES, Fan YH, El-Naggar AK, Hong WK, Myers J, Papadimitrakopoulou V, ... Issa J, et al. New DNA methylation markers associated with oral cancer (OC) development (dvlpt). Journal of Clinical Oncology. 30: 5524-5524. DOI: 10.1200/Jco.2012.30.15_Suppl.5524 |
0.516 |
|
| 2012 |
Gough SM, Chung YJ, Shinji M, Jelinek J, Issa J, Aplan P. Mice with Myelodysplastic Syndrome Respond to Treatment with Azanucleosides: A Preclinical Model for MDS Therapies Blood. 120: 3829-3829. DOI: 10.1182/Blood.V120.21.3829.3829 |
0.406 |
|
| 2012 |
Tsai H, Li H, Neste LV, Cai Y, Robert C, Rassool FV, Shin JJ, Harbom KM, Beaty R, Pappou E, Harris J, Yen RC, Ahuja N, Brock MV, Stearns V, ... ... Issa J, et al. Abstract 995: Transient low doses of DNA demethylating agents exert durable antitumor effects on hematological and epithelial tumor cells Cancer Research. 72: 995-995. DOI: 10.1158/1538-7445.Am2012-995 |
0.509 |
|
| 2012 |
Kleb BN, Estecio M, Zhang J, Tzelepi V, Chung W, Maity S, Logothetis C, Troncoso P, Navone N, Jelinek J, Liang S, Issa J, Aparicio A. Abstract 991: The DNA methylome of castration-resistant prostate cancer Cancer Research. 72: 991-991. DOI: 10.1158/1538-7445.Am2012-991 |
0.441 |
|
| 2012 |
Plimack ER, Issa J, Jelinek J, Sharma P, Vence L, Bassett RL, Ilagan JL, Papadopoulos NE, Hwu W. Abstract 5590: A phase I/II study of decitabine with pegylated interferon α-2b in advanced melanoma: clinical results and impact on DNA methylation and immune modulation Cancer Research. 72: 5590-5590. DOI: 10.1158/1538-7445.Am2012-5590 |
0.371 |
|
| 2012 |
Czerniak BA, Majewski T, Bondaruk J, Zhang S, Lee S, Baggerly K, Dinney C, Grossman HB, Wu X, Issa J, Zhang W, Gibbs R, Scherer SE. Abstract 5066: Genome sequence and epigenome map of bladder cancer development from occult field effects Cancer Research. 72: 5066-5066. DOI: 10.1158/1538-7445.Am2012-5066 |
0.373 |
|
| 2012 |
Guillaumet A, Sandoval J, Esteller M, Issa J, Sibert R, Monk D. Abstract 4021: Breaking the dogma: AWT1 hypermethylation in myeloid leukemia despite high expression Cancer Research. 72: 4021-4021. DOI: 10.1158/1538-7445.Am2012-4021 |
0.551 |
|
| 2011 |
Konishi K, Watanabe Y, Shen L, Guo Y, Castoro RJ, Kondo K, Chung W, Ahmed S, Jelinek J, Boumber YA, Estecio MR, Maegawa S, Kondo Y, Itoh F, Imawari M, ... ... Issa JP, et al. DNA methylation profiles of primary colorectal carcinoma and matched liver metastasis. Plos One. 6: e27889. PMID 22132162 DOI: 10.1371/Journal.Pone.0027889 |
0.699 |
|
| 2011 |
Qin T, Castoro R, El Ahdab S, Jelinek J, Wang X, Si J, Shu J, He R, Zhang N, Chung W, Kantarjian HM, Issa JP. Mechanisms of resistance to decitabine in the myelodysplastic syndrome. Plos One. 6: e23372. PMID 21858090 DOI: 10.1371/Journal.Pone.0023372 |
0.744 |
|
| 2011 |
Issa JP. Epigenetic variation and cellular Darwinism Nature Genetics. 43: 724-726. PMID 21792236 DOI: 10.1038/Ng.897 |
0.483 |
|
| 2011 |
Jelinek J, Gharibyan V, Estecio MR, Kondo K, He R, Chung W, Lu Y, Zhang N, Liang S, Kantarjian HM, Cortes JE, Issa JP. Aberrant DNA methylation is associated with disease progression, resistance to imatinib and shortened survival in chronic myelogenous leukemia. Plos One. 6: e22110. PMID 21760961 DOI: 10.1371/Journal.Pone.0022110 |
0.484 |
|
| 2011 |
Issa JP, Just W. Epigenetics. Febs Letters. 585: 1993. PMID 21693122 DOI: 10.1016/j.febslet.2011.06.007 |
0.326 |
|
| 2011 |
Chung W, Bondaruk J, Jelinek J, Lotan Y, Liang S, Czerniak B, Issa JP. Detection of bladder cancer using novel DNA methylation biomarkers in urine sediments. Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association For Cancer Research, Cosponsored by the American Society of Preventive Oncology. 20: 1483-91. PMID 21586619 DOI: 10.1158/1055-9965.Epi-11-0067 |
0.36 |
|
| 2011 |
Boumber Y, Issa JPJ. Epigenetics in cancer: what's the future? Oncology (Williston Park, N.Y.). 25. PMID 21548464 DOI: 10.1016/j.febslet.2011.06.007 |
0.738 |
|
| 2011 |
Ahn JB, Chung WB, Maeda O, Shin SJ, Kim HS, Chung HC, Kim NK, Issa JP. DNA methylation predicts recurrence from resected stage III proximal colon cancer. Cancer. 117: 1847-54. PMID 21509761 DOI: 10.1002/cncr.25737 |
0.336 |
|
| 2011 |
Pathiraja TN, Shetty PB, Jelinek J, He R, Hartmaier R, Margossian AL, Hilsenbeck SG, Issa JP, Oesterreich S. Progesterone receptor isoform-specific promoter methylation: association of PRA promoter methylation with worse outcome in breast cancer patients. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 17: 4177-86. PMID 21459801 DOI: 10.1158/1078-0432.CCR-10-2950 |
0.344 |
|
| 2011 |
Cogdell D, Chung W, Liu Y, McDonald JM, Aldape K, Issa JP, Fuller GN, Zhang W. Tumor-associated methylation of the putative tumor suppressor AJAP1 gene and association between decreased AJAP1 expression and shorter survival in patients with glioma. Chinese Journal of Cancer. 30: 247-53. PMID 21439246 DOI: 10.5732/Cjc.011.10025 |
0.409 |
|
| 2011 |
Estécio MRH, Issa JPJ. Dissecting DNA hypermethylation in cancer Febs Letters. 585: 2078-2086. PMID 21146531 DOI: 10.1016/j.febslet.2010.12.001 |
0.473 |
|
| 2011 |
Jelinek J, Liang S, Neumann F, He R, Lu Y, Yamazaki J, Taby RF, Ramagli L, Estecio MR, Issa J. Cancer Drivers Affected by Aberrant DNA Methylation in MDS and AML Blood. 118: 1716-1716. DOI: 10.1182/Blood.V118.21.1716.1716 |
0.54 |
|
| 2011 |
Boumber Y, Issa J, Jorgensen JL, Faderl S, Castoro RJ, Autry J, Garcia-Manero G, Borthakur G, Jabbour E, Estrov Z, Cortes JE, Kantarjian HM, Ravandi F. Final Report of a Randomized Study of Decitabine Versus Conventional Care (CC) for Maintenance Therapy in Patients with Intermediate and High Risk Acute Myeloid Leukemia (AML) in First or Subsequent Complete Remission (CR) Blood. 118: 1530-1530. DOI: 10.1182/Blood.V118.21.1530.1530 |
0.657 |
|
| 2011 |
Yamazaki J, Taby RF, Vasanthakumar A, Macrae T, Ostler KR, Shen L, Kantarjian HM, Estecio MR, Jelinek J, Godley L, Issa J. Limited Effect of TET2 Mutations on Promoter DNA Methylation in Chronic Myelomonocytic Leukemia Blood. 118: 1365-1365. DOI: 10.1182/Blood.V118.21.1365.1365 |
0.503 |
|
| 2011 |
Czerniak B, Majewski T, Chung W, Limei H, Cogdell D, Bondaruk J, Zhang S, Lee S, Lee S, Shen L, Wei C, Yoo SY, Choi W, McConkey D, Weinstein J, ... ... Issa J, et al. Abstract 4837: Integrated genome sequence, epigenome, and transcriptome map of bladder cancer development Cancer Research. 71: 4837-4837. DOI: 10.1158/1538-7445.Am2011-4837 |
0.384 |
|
| 2011 |
Estecio MRH, Dekmezian M, Gallegos J, Liang S, Issa J. Abstract 2791: SINE retrotransposons cause epigenetic reprogramming of adjacent gene promoters Cancer Research. 71: 2791-2791. DOI: 10.1158/1538-7445.Am2011-2791 |
0.492 |
|
| 2010 |
Wallace K, Grau MV, Levine AJ, Shen L, Hamdan R, Chen X, Gui J, Haile RW, Barry EL, Ahnen D, McKeown-Eyssen G, Baron JA, Issa JP. Association between folate levels and CpG Island hypermethylation in normal colorectal mucosa. Cancer Prevention Research (Philadelphia, Pa.). 3: 1552-64. PMID 21149331 DOI: 10.1158/1940-6207.Capr-10-0047 |
0.365 |
|
| 2010 |
Taby R, Issa JP. Cancer epigenetics Ca Cancer Journal For Clinicians. 60: 376-392. PMID 20959400 DOI: 10.3322/caac.20085 |
0.371 |
|
| 2010 |
Estécio MR, Gallegos J, Vallot C, Castoro RJ, Chung W, Maegawa S, Oki Y, Kondo Y, Jelinek J, Shen L, Hartung H, Aplan PD, Czerniak BA, Liang S, Issa JP. Genome architecture marked by retrotransposons modulates predisposition to DNA methylation in cancer. Genome Research. 20: 1369-82. PMID 20716667 DOI: 10.1101/Gr.107318.110 |
0.476 |
|
| 2010 |
Si J, Boumber YA, Shu J, Qin T, Ahmed S, He R, Jelinek J, Issa JP. Chromatin remodeling is required for gene reactivation after decitabine-mediated DNA hypomethylation. Cancer Research. 70: 6968-77. PMID 20713525 DOI: 10.1158/0008-5472.Can-09-4474 |
0.77 |
|
| 2010 |
Kondo Y, Issa JPJ. DNA methylation profiling in cancer Expert Reviews in Molecular Medicine. 12. PMID 20663272 DOI: 10.1017/S1462399410001559 |
0.443 |
|
| 2010 |
Kwabi-Addo B, Wang S, Chung W, Jelinek J, Patierno SR, Wang BD, Andrawis R, Lee NH, Apprey V, Issa JP, Ittmann M. Identification of differentially methylated genes in normal prostate tissues from African American and Caucasian men. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 16: 3539-47. PMID 20606036 DOI: 10.1158/1078-0432.Ccr-09-3342 |
0.376 |
|
| 2010 |
Issa JP. Epigenetic changes in the myelodysplastic syndrome Hematology/Oncology Clinics of North America. 24: 317-330. PMID 20359628 DOI: 10.1016/J.Hoc.2010.02.007 |
0.539 |
|
| 2010 |
Oki Y, Issa JPJ. Epigenetic mechanisms in AML - A target for therapy Cancer Treatment and Research. 145: 19-40. PMID 20306243 DOI: 10.1007/978-0-387-69259-3_2 |
0.431 |
|
| 2010 |
An B, Kondo Y, Okamoto Y, Shinjo K, Kanemitsu Y, Komori K, Hirai T, Sawaki A, Tajika M, Nakamura T, Yamao K, Yatabe Y, Fujii M, Murakami H, Osada H, ... ... Issa JP, et al. Characteristic methylation profile in CpG island methylator phenotype-negative distal colorectal cancers. International Journal of Cancer. Journal International Du Cancer. 127: 2095-105. PMID 20131317 DOI: 10.1002/ijc.25225 |
0.44 |
|
| 2010 |
Maegawa S, Hinkal G, Kim HS, Shen L, Zhang L, Zhang J, Zhang N, Liang S, Donehower LA, Issa JP. Widespread and tissue specific age-related DNA methylation changes in mice. Genome Research. 20: 332-40. PMID 20107151 DOI: 10.1101/Gr.096826.109 |
0.366 |
|
| 2010 |
Shen L, Kantarjian H, Guo Y, Lin E, Shan J, Huang X, Berry D, Ahmed S, Zhu W, Pierce S, Kondo Y, Oki Y, Jelinek J, Saba H, Estey E, ... Issa JP, et al. DNA methylation predicts survival and response to therapy in patients with myelodysplastic syndromes. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 28: 605-13. PMID 20038729 DOI: 10.1200/JCO.2009.23.4781 |
0.308 |
|
| 2010 |
Santos FP, Kantarjian H, Garcia-Manero G, Issa JP, Ravandi F. Decitabine in the treatment of myelodysplastic syndromes. Expert Review of Anticancer Therapy. 10: 9-22. PMID 20014881 DOI: 10.1586/era.09.164 |
0.343 |
|
| 2010 |
Suzuki H, Igarashi S, Nojima M, Maruyama R, Yamamoto E, Kai M, Akashi H, Watanabe Y, Yamamoto H, Sasaki Y, Itoh F, Imai K, Sugai T, Shen L, Issa JPJ, et al. IGFBP7 is a p53-responsive gene specifically silenced in colorectal cancer with CpG island methylator phenotype Carcinogenesis. 31: 342-349. PMID 19638426 DOI: 10.1093/carcin/bgp179 |
0.43 |
|
| 2010 |
Kashani FR, Jorgensen J, Faderl S, Issa J, Autry J, Garcia-Manero G, Borthakur G, Huang X, Cortes JE, Kantarjian H. Randomized study of decitabine versus conventional care (CC) in patients (pts) with intermediate- and high-risk acute myeloid leukemia (AML) in first or subsequent complete remission (CR). Journal of Clinical Oncology. 28: 6527-6527. DOI: 10.1200/Jco.2010.28.15_Suppl.6527 |
0.336 |
|
| 2010 |
Yamazaki J, Estecio MR, Jelinek J, Graber D, Lu Y, Ramagli L, Liang S, Kornblau SM, Issa J. Genome-Wide Epigenetic Analysis of Cancer Stem Cells (CSCs) In Acute Myeloid Leukemia. Blood. 116: 3640-3640. DOI: 10.1182/Blood.V116.21.3640.3640 |
0.479 |
|
| 2010 |
Neumann F, Issa J, Lu Y, Estecio MR, He R, Ramagli L, Liang S, Jelinek J. Digital Restriction Enzyme Analysis of Methylation (DREAM) by Next Generation Sequencing Uncovers Epigenetic Disturbances In Acute Myelogenous Leukemia. Blood. 116: 3635-3635. DOI: 10.1182/Blood.V116.21.3635.3635 |
0.527 |
|
| 2010 |
Yan Z, Shu J, Si J, Qin T, Estecio MR, Issa J. Abstract LB-84: DNA methylation centers in CpG-island promoters are context-specific Cancer Research. 70. DOI: 10.1158/1538-7445.Am10-Lb-84 |
0.812 |
|
| 2009 |
Stewart DJ, Nunez MI, Jelinek J, Guo Z, Hong D, Gupta S, Oki Y, Issa J, Kurzrock R, Wistuba II. Decitabine effect on human tumor expression of various transporters. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 2540. PMID 27961867 DOI: 10.1200/Jco.2009.27.15_Suppl.2540 |
0.383 |
|
| 2009 |
Liang S, Lu Y, Jelinek J, Estecio M, Li H, Issa JP. Analysis of epigenetic modifications by next generation sequencing. Conference Proceedings : ... Annual International Conference of the Ieee Engineering in Medicine and Biology Society. Ieee Engineering in Medicine and Biology Society. Annual Conference. 2009: 6730. PMID 19963934 DOI: 10.1109/IEMBS.2009.5332853 |
0.395 |
|
| 2009 |
Estécio MR, Issa JP. Tackling the methylome: recent methodological advances in genome-wide methylation profiling. Genome Medicine. 1: 106. PMID 19930617 DOI: 10.1186/gm106 |
0.452 |
|
| 2009 |
Goto Y, Shinjo K, Kondo Y, Shen L, Toyota M, Suzuki H, Gao W, An B, Fujii M, Murakami H, Osada H, Taniguchi T, Usami N, Kondo M, Hasegawa Y, ... ... Issa JP, et al. Epigenetic profiles distinguish malignant pleural mesothelioma from lung adenocarcinoma. Cancer Research. 69: 9073-82. PMID 19887624 DOI: 10.1158/0008-5472.CAN-09-1595 |
0.453 |
|
| 2009 |
Konishi K, Shen L, Jelinek J, Watanabe Y, Ahmed S, Kaneko K, Kogo M, Takano T, Imawari M, Hamilton SR, Issa JP. Concordant DNA methylation in synchronous colorectal carcinomas. Cancer Prevention Research (Philadelphia, Pa.). 2: 814-22. PMID 19737982 DOI: 10.1158/1940-6207.CAPR-09-0054 |
0.323 |
|
| 2009 |
Issa JPJ, Kantarjian HM. Targeting DNA methylation Clinical Cancer Research. 15: 3938-3946. PMID 19509174 DOI: 10.1158/1078-0432.CCR-08-2783 |
0.462 |
|
| 2009 |
Stewart DJ, Issa JP, Kurzrock R, Nunez MI, Jelinek J, Hong D, Oki Y, Guo Z, Gupta S, Wistuba II. Decitabine effect on tumor global DNA methylation and other parameters in a phase I trial in refractory solid tumors and lymphomas. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 15: 3881-8. PMID 19470736 DOI: 10.1158/1078-0432.Ccr-08-2196 |
0.331 |
|
| 2009 |
Tellez CS, Shen L, Estécio MR, Jelinek J, Gershenwald JE, Issa JP. CpG island methylation profiling in human melanoma cell lines. Melanoma Research. 19: 146-55. PMID 19441164 |
0.398 |
|
| 2009 |
Aparicio A, North B, Barske L, Wang X, Bollati V, Weisenberger D, Yoo C, Tannir N, Horne E, Groshen S, Jones P, Yang A, Issa JP. LINE-1 methylation in plasma DNA as a biomarker of activity of DNA methylation inhibitors in patients with solid tumors. Epigenetics. 4: 176-84. PMID 19421002 DOI: 10.4161/Epi.4.3.8694 |
0.496 |
|
| 2009 |
Batty N, Malouf GG, Issa JPJ. Histone deacetylase inhibitors as anti-neoplastic agents Cancer Letters. 280: 192-200. PMID 19345475 DOI: 10.1016/j.canlet.2009.03.013 |
0.332 |
|
| 2009 |
Figueiredo JC, Grau MV, Wallace K, Levine AJ, Shen L, Hamdan R, Chen X, Bresalier RS, McKeown-Eyssen G, Haile RW, Baron JA, Issa JP. Global DNA hypomethylation (LINE-1) in the normal colon and lifestyle characteristics and dietary and genetic factors. Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association For Cancer Research, Cosponsored by the American Society of Preventive Oncology. 18: 1041-9. PMID 19336559 DOI: 10.1158/1055-9965.Epi-08-0926 |
0.325 |
|
| 2009 |
Qin T, Jelinek J, Si J, Shu J, Issa JP. Mechanisms of resistance to 5-aza-2'-deoxycytidine in human cancer cell lines. Blood. 113: 659-67. PMID 18931345 DOI: 10.1182/Blood-2008-02-140038 |
0.764 |
|
| 2009 |
Pathiraja T, Jelinek J, He R, Shetty P, Hartmaier R, Margossian A, Hilsenbeck S, Issa J, Oesterreich S. Progesterone Receptor (PR) Promoter Methylation – Role as a Predictive and Prognostic Marker in Breast Cancer. Cancer Research. 69: 2002-2002. DOI: 10.1158/0008-5472.Sabcs-09-2002 |
0.36 |
|
| 2008 |
Estécio MR, Yan PS, Huang TH, Issa JP. Methylated CpG Island Amplification and Microarray (MCAM) for High-Throughput Analysis of DNA Methylation. Csh Protocols. 2008: pdb.prot4974. PMID 21356790 DOI: 10.1101/Pdb.Prot4974 |
0.412 |
|
| 2008 |
Issa JP. Cancer prevention: Epigenetics steps up to the plate Cancer Prevention Research. 1: 219-222. PMID 19138962 DOI: 10.1158/1940-6207.Capr-08-0029 |
0.395 |
|
| 2008 |
Issa JP. Colon cancer: It's CINor CIMP Clinical Cancer Research. 14: 5939-5940. PMID 18829469 DOI: 10.1158/1078-0432.Ccr-08-1596 |
0.352 |
|
| 2008 |
Boumber YA, Kondo Y, Chen X, Shen L, Guo Y, Tellez C, Estécio MR, Ahmed S, Issa JP. An Sp1/Sp3 binding polymorphism confers methylation protection. Plos Genetics. 4: e1000162. PMID 18725933 DOI: 10.1371/Journal.Pgen.1000162 |
0.712 |
|
| 2008 |
Gao W, Kondo Y, Shen L, Shimizu Y, Sano T, Yamao K, Natsume A, Goto Y, Ito M, Murakami H, Osada H, Zhang J, Issa JP, Sekido Y. Variable DNA methylation patterns associated with progression of disease in hepatocellular carcinomas. Carcinogenesis. 29: 1901-10. PMID 18632756 DOI: 10.1093/carcin/bgn170 |
0.301 |
|
| 2008 |
Kroeger H, Jelinek J, Estécio MR, He R, Kondo K, Chung W, Zhang L, Shen L, Kantarjian HM, Bueso-Ramos CE, Issa JP. Aberrant CpG island methylation in acute myeloid leukemia is accentuated at relapse. Blood. 112: 1366-73. PMID 18523155 DOI: 10.1182/blood-2007-11-126227 |
0.471 |
|
| 2008 |
Kondo Y, Shen L, Cheng AS, Ahmed S, Boumber Y, Charo C, Yamochi T, Urano T, Furukawa K, Kwabi-Addo B, Gold DL, Sekido Y, Huang TH, Issa JP. Gene silencing in cancer by histone H3 lysine 27 trimethylation independent of promoter DNA methylation. Nature Genetics. 40: 741-50. PMID 18488029 DOI: 10.1038/Ng.159 |
0.753 |
|
| 2008 |
Lee ES, Issa JP, Roberts DB, Williams MD, Weber RS, Kies MS, El-Naggar AK. Quantitative promoter hypermethylation analysis of cancer-related genes in salivary gland carcinomas: comparison with methylation-specific PCR technique and clinical significance. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 14: 2664-72. PMID 18451230 DOI: 10.1158/1078-0432.CCR-07-1232 |
0.364 |
|
| 2008 |
Chung W, Kwabi-Addo B, Ittmann M, Jelinek J, Shen L, Yu Y, Issa JP. Identification of novel tumor markers in prostate, colon and breast cancer by unbiased methylation profiling. Plos One. 3: e2079. PMID 18446232 DOI: 10.1371/Journal.Pone.0002079 |
0.372 |
|
| 2008 |
Kondo Y, Shen L, Ahmed S, Boumber Y, Sekido Y, Haddad BR, Issa JPJ. Downregulation of histone H3 lysine 9 methyltransferase G9a induces centrosome disruption and chromosome instability in cancer cells. Plos One. 3. PMID 18446223 DOI: 10.1371/Journal.Pone.0002037 |
0.685 |
|
| 2008 |
Feng W, Marquez RT, Lu Z, Liu J, Lu KH, Issa JP, Fishman DM, Yu Y, Bast RC. Imprinted tumor suppressor genes ARHI and PEG3 are the most frequently down-regulated in human ovarian cancers by loss of heterozygosity and promoter methylation. Cancer. 112: 1489-502. PMID 18286529 DOI: 10.1002/Cncr.23323 |
0.333 |
|
| 2008 |
Zuo X, Shen L, Issa JP, Moy O, Morris JS, Lippman SM, Shureiqi I. 15-Lipoxygenase-1 transcriptional silencing by DNA methyltransferase-1 independently of DNA methylation. Faseb Journal : Official Publication of the Federation of American Societies For Experimental Biology. 22: 1981-92. PMID 18198215 DOI: 10.1096/fj.07-098301 |
0.492 |
|
| 2008 |
Shen L, Kondo Y, Ahmed S, Boumber Y, Konishi K, Guo Y, Chen X, Vilaythong JN, Issa JP. Drug sensitivity prediction by CpG island methylation profile in the NCI-60 cancer cell line panel. Cancer Research. 67: 11335-43. PMID 18056460 DOI: 10.1158/0008-5472.Can-07-1502 |
0.74 |
|
| 2008 |
Issa J, Castoro R, Ravandi-Kashani F, Faderl S, Huang X, Estey E, Borthakur G, Morris G, Garcia-Manero G, Kantarjian HM. Randomized Phase II Study of Combined Epigenetic Therapy: Decitabine Vs. Decitabine and Valproic Acid in MDS and AML Blood. 112: 228-228. DOI: 10.1182/Blood.V112.11.228.228 |
0.41 |
|
| 2007 |
Oki Y, Issa JPJ. Treatment options in advanced myelodysplastic syndrome, with emphasis on epigenetic therapy International Journal of Hematology. 86: 306-314. PMID 18055336 DOI: 10.1532/IJH97.07034 |
0.339 |
|
| 2007 |
Wang J, Bhutani M, Pathak AK, Lang W, Ren H, Jelinek J, He R, Shen L, Issa J, Mao L. Delta DNMT3B variants regulate DNA methylation in a promoter-specific manner. Cancer Research. 67: 10647-10652. PMID 18006804 DOI: 10.1158/0008-5472.Can-07-1337 |
0.559 |
|
| 2007 |
Jelinek J, Li J, Mnjoyan Z, Issa JP, Prchal JT, Afshar-Kharghan V. Epigenetic control of PRV-1 expression on neutrophils. Experimental Hematology. 35: 1677-83. PMID 17976520 DOI: 10.1016/j.exphem.2007.09.008 |
0.3 |
|
| 2007 |
Shen L, Kondo Y, Guo Y, Zhang J, Zhang L, Ahmed S, Shu J, Chen X, Waterland RA, Issa JP. Genome-wide profiling of DNA methylation reveals a class of normally methylated CpG island promoters. Plos Genetics. 3: 2023-36. PMID 17967063 DOI: 10.1371/Journal.Pgen.0030181 |
0.828 |
|
| 2007 |
Shen L, Catalano PJ, Benson AB, O'Dwyer P, Hamilton SR, Issa JP. Association between DNA methylation and shortened survival in patients with advanced colorectal cancer treated with 5-fluorouracil based chemotherapy. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 13: 6093-8. PMID 17947473 DOI: 10.1158/1078-0432.Ccr-07-1011 |
0.337 |
|
| 2007 |
Estécio MR, Yan PS, Ibrahim AE, Tellez CS, Shen L, Huang TH, Issa JP. High-throughput methylation profiling by MCA coupled to CpG island microarray. Genome Research. 17: 1529-36. PMID 17785535 DOI: 10.1101/Gr.6417007 |
0.438 |
|
| 2007 |
Feng W, Shen L, Wen S, Rosen DG, Jelinek J, Hu X, Huan S, Huang M, Liu J, Sahin AA, Hunt KK, Bast RC, Shen Y, Issa JP, Yu Y. Correlation between CpG methylation profiles and hormone receptor status in breast cancers. Breast Cancer Research : Bcr. 9: R57. PMID 17764565 DOI: 10.1186/Bcr1762 |
0.318 |
|
| 2007 |
Plimack ER, Kantarjian HM, Issa JP. Decitabine and its role in the treatment of hematopoietic malignancies Leukemia and Lymphoma. 48: 1472-1481. PMID 17701577 DOI: 10.1080/10428190701471981 |
0.407 |
|
| 2007 |
Choi SH, Byun HM, Kwan JM, Issa JP, Yang AS. Hydroxycarbamide in combination with azacitidine or decitabine is antagonistic on DNA methylation inhibition. British Journal of Haematology. 138: 616-23. PMID 17686055 DOI: 10.1111/J.1365-2141.2007.06707.X |
0.412 |
|
| 2007 |
Qin T, Youssef EM, Jelinek J, Chen R, Yang AS, Garcia-Manero G, Issa JP. Effect of cytarabine and decitabine in combination in human leukemic cell lines. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 13: 4225-32. PMID 17634552 DOI: 10.1158/1078-0432.Ccr-06-2762 |
0.772 |
|
| 2007 |
Kwabi-Addo B, Chung W, Shen L, Ittmann M, Wheeler T, Jelinek J, Issa JP. Age-related DNA methylation changes in normal human prostate tissues. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 13: 3796-802. PMID 17606710 DOI: 10.1158/1078-0432.Ccr-07-0085 |
0.338 |
|
| 2007 |
Kondo Y, Shen L, Suzuki S, Kurokawa T, Masuko K, Tanaka Y, Kato H, Mizuno Y, Yokoe M, Sugauchi F, Hirashima N, Orito E, Osada H, Ueda R, Guo Y, ... ... Issa JP, et al. Alterations of DNA methylation and histone modifications contribute to gene silencing in hepatocellular carcinomas. Hepatology Research : the Official Journal of the Japan Society of Hepatology. 37: 974-83. PMID 17584191 DOI: 10.1111/j.1872-034X.2007.00141.x |
0.324 |
|
| 2007 |
Estécio MR, Gharibyan V, Shen L, Ibrahim AE, Doshi K, He R, Jelinek J, Yang AS, Yan PS, Huang TH, Tajara EH, Issa JP. LINE-1 hypomethylation in cancer is highly variable and inversely correlated with microsatellite instability. Plos One. 2: e399. PMID 17476321 DOI: 10.1371/Journal.Pone.0000399 |
0.407 |
|
| 2007 |
Konishi K, Issa JPJ. Targeting aberrant chromatin structure in colorectal carcinomas Cancer Journal. 13: 49-55. PMID 17464246 DOI: 10.1097/PPO.0b013e31803c72fe |
0.494 |
|
| 2007 |
Konishi K, Shen L, Wang S, Meltzer SJ, Harpaz N, Issa JP. Rare CpG island methylator phenotype in ulcerative colitis-associated neoplasias. Gastroenterology. 132: 1254-60. PMID 17408633 DOI: 10.1053/J.Gastro.2007.01.035 |
0.31 |
|
| 2007 |
Issa JPJ. DNA methylation as a therapeutic target in cancer Clinical Cancer Research. 13: 1634-1637. PMID 17363514 DOI: 10.1158/1078-0432.CCR-06-2076 |
0.485 |
|
| 2007 |
Jelinek J, Issa JP, He R, Cmejla R, Cmejlova J, Pospisilova D. RPS19 and JAK2 genes are not silenced by DNA methylation in diamond blackfan anemia. Journal of Pediatric Hematology/Oncology. 29: 207-8. PMID 17356406 DOI: 10.1097/MPH.0b013e318033a75a |
0.432 |
|
| 2007 |
Boumber YA, Kondo Y, Chen X, Shen L, Gharibyan V, Konishi K, Estey E, Kantarjian H, Garcia-Manero G, Issa JP. RIL, a LIM gene on 5q31, is silenced by methylation in cancer and sensitizes cancer cells to apoptosis. Cancer Research. 67: 1997-2005. PMID 17332327 DOI: 10.1158/0008-5472.Can-06-3093 |
0.738 |
|
| 2007 |
Shen L, Issa JP. Epigenetics in colorectal cancer. Current Opinion in Gastroenterology. 18: 68-73. PMID 17031233 DOI: 10.1097/00001574-200201000-00012 |
0.436 |
|
| 2007 |
Oki Y, Aoki E, Issa JPJ. Decitabine-Bedside to bench Critical Reviews in Oncology/Hematology. 61: 140-152. PMID 17023173 DOI: 10.1016/j.critrevonc.2006.07.010 |
0.336 |
|
| 2007 |
Borthakur G, Kantarjian H, O’Brien S, Ravandi F, Koller C, Estrov Z, Torma R, Issa J. Report of a Phase1/2 Study of 5-Azacitidine and Cytarabine in Patients with Relapsed, Refractory Acute Myelogenous Leukemia. Blood. 110: 911-911. DOI: 10.1182/Blood.V110.11.911.911 |
0.383 |
|
| 2007 |
Ravandi F, Faderl S, Thomas D, Burger J, Koller C, Garcia-Manero G, Morris G, Torma R, Kantarjian H, Issa J. Phase I Study of Suberoylanilide Hydroxamic Acid (SAHA) and Decitabine in Patients with Relapsed, Refractory or Poor Prognosis Leukemia. Blood. 110: 897-897. DOI: 10.1182/Blood.V110.11.897.897 |
0.389 |
|
| 2007 |
Kroeger H, Jelinek J, Kornblau SM, Bueso-Ramos CE, Issa J. Increased DNA Methylation Is Associated with Good Prognosis in AML. Blood. 110: 595-595. DOI: 10.1182/Blood.V110.11.595.595 |
0.482 |
|
| 2007 |
Ahdab SE, Castoro R, Abbas HA, Ahmed S, Jelinek J, Issa J. Methylation Profiling of Apoptotic Genes in Leukemia Cell Lines and Patients. Blood. 110: 4147-4147. DOI: 10.1182/Blood.V110.11.4147.4147 |
0.528 |
|
| 2007 |
Ravandi F, Issa J, Faderl S, Garcia-Manero G, Hood M, Jorgensen J, Lee M, O’Brien S, Estey E, Borthakur G, Ferrajoli A, Verstovsek S, Cortes J, Kantarjian H. Randomized Study of Decitabine Versus Observation or Continued Cytotoxic Chemotherapy in Patients with Intermediate and Poor Risk Acute Myeloid Leukemia in First or Subsequent Complete Remission. Blood. 110: 2859-2859. DOI: 10.1182/Blood.V110.11.2859.2859 |
0.346 |
|
| 2007 |
Kuang S, Tong W, Yang H, Lee MK, Fang Z, Jelinek J, Issa J, Garcia-Manero G. Genome-Wide Identification of Aberrant Promoter Associated CpG Island Methylation in Acute Lymphoblastic Leukemia. Blood. 110: 2127-2127. DOI: 10.1182/Blood.V110.11.2127.2127 |
0.574 |
|
| 2007 |
Heinrichs S, Kulkarni RV, Bueso-Ramos CE, Loh M, Levine R, Li C, Neuberg DS, Kornblau SM, Issa J, Gilliland DG, Estey EH, Look AT. Large Regions of Uniparental Disomy (UPD) Establish Clonal Hematopoietic Stem Cell Selection in a Subset of Myelodysplastic Syndrome (MDS) Patients with Normal Bone Marrow Cell Karyotypes. Blood. 110: 120-120. DOI: 10.1182/Blood.V110.11.120.120 |
0.321 |
|
| 2006 |
Soriano AO, Yang H, Verstovsek S, Wierda W, Koller C, Estrov Z, Ouzounian S, Kantarjian H, Issa J, Garcia-Manero G. Phase I/II study of the combination of 5-azacytidine(5-AC), all-trans retinoic acid (ATRA) and valproic Acid (VPA) in patients with myelodysplastic syndrome (MDS) and leukemia. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 24: 6563. PMID 27953109 DOI: 10.1200/Jco.2006.24.18_Suppl.6563 |
0.336 |
|
| 2006 |
Oki Y, Issa JPJ. Review: recent clinical trials in epigenetic therapy Reviews On Recent Clinical Trials. 1: 169-182. PMID 18473969 DOI: 10.2174/157488706776876490 |
0.35 |
|
| 2006 |
Montero AJ, Díaz-Montero CM, Mao L, Youssef EM, Estecio M, Shen L, Issa JP. Epigenetic inactivation of EGFR by CpG island hypermethylation in cancer. Cancer Biology & Therapy. 5: 1494-501. PMID 17369752 DOI: 10.4161/cbt.5.11.3299 |
0.312 |
|
| 2006 |
Tabe Y, Konopleva M, Kondo Y, Contractor R, Jin L, Ruvolo V, Tsutsumi-Ishii Y, Miyake K, Miyake N, Ohsaka A, Nagaoka I, Issa JP, Andreeff M. PML-RARalpha and AML1-ETO translocations are rarely associated with methylation of the RARbeta2 promoter. Annals of Hematology. 85: 689-704. PMID 16832676 DOI: 10.1007/S00277-006-0148-7 |
0.458 |
|
| 2006 |
Yang AS, Doshi KD, Choi SW, Mason JB, Mannari RK, Gharybian V, Luna R, Rashid A, Shen L, Estecio MR, Kantarjian HM, Garcia-Manero G, Issa JP. DNA methylation changes after 5-aza-2'-deoxycytidine therapy in patients with leukemia. Cancer Research. 66: 5495-503. PMID 16707479 DOI: 10.1158/0008-5472.CAN-05-2385 |
0.379 |
|
| 2006 |
Shu J, Jelinek J, Chang H, Shen L, Qin T, Chung W, Oki Y, Issa JP. Silencing of bidirectional promoters by DNA methylation in tumorigenesis. Cancer Research. 66: 5077-84. PMID 16707430 DOI: 10.1158/0008-5472.Can-05-2629 |
0.813 |
|
| 2006 |
Kantarjian H, Issa JP, Rosenfeld CS, Bennett JM, Albitar M, DiPersio J, Klimek V, Slack J, de Castro C, Ravandi F, Helmer R, Shen L, Nimer SD, Leavitt R, Raza A, et al. Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study. Cancer. 106: 1794-803. PMID 16532500 DOI: 10.1002/cncr.21792 |
0.311 |
|
| 2006 |
Byun H, Eshaghian S, Jiang JY, Choi SH, Ramezani L, Douer D, Garcia-Manero G, Issa J, Yang D, Trent J, Yang AS. Methylation Profiling of Three Homogenous Cancers: Chronic Myelogenous Leukemia (CML), Acute Promyelocytic Leukemia (APL) and Gastrointestinal Stromal Tumors (GIST). Blood. 108: 736-736. DOI: 10.1182/Blood.V108.11.736.736 |
0.573 |
|
| 2006 |
Plasilova M, Ommen HB, Jelinek J, Issa J, Riedel ER, Mathew S, Chadburn A, Zhou P, Hokland P, Moore MAS. Loss of Heterozygosity (LOH) of the NUP98 Gene Is an Adverse Prognostic Factor in Acute Myeloid Leukemia (AML). Blood. 108: 2356-2356. DOI: 10.1182/Blood.V108.11.2356.2356 |
0.343 |
|
| 2006 |
Loboda A, Fantin VR, Bueso-Ramos CE, Randolph S, Hardwick JS, Ricker JL, Richon VM, Issa J, Kantarjian HM, Frankel SR, Garcia-Manero G. Clinical Responses to Oral Vorinostat (Suberoylanilide Hydroxamic Acid, SAHA) Are Associated with Specific Gene Expression Signatures in Patients with Advanced Leukemias: Results of a Phase I Trial. Blood. 108: 2320-2320. DOI: 10.1182/Blood.V108.11.2320.2320 |
0.374 |
|
| 2006 |
Garcia-Manero G, Yang AS, Giles F, Faderl S, Ravandi F, Cortes J, Newsome WM, Issa J, Patterson T, Dubay M, Li Z, Kantarjian H, Martell RE. Phase I/II Study of the Oral Isotype-Selective Histone Deacetylase (HDAC) Inhibitor MGCD0103 in Combination with Azacitidine in Patients (pts) with High-Risk Myelodysplastic Syndrome (MDS) or Acute Myelogenous Leukemia (AML). Blood. 108: 1954-1954. DOI: 10.1182/Blood.V108.11.1954.1954 |
0.373 |
|
| 2006 |
Soriano AO, Yang H, Tong W, Faderl S, Wierda W, Andreeff M, Estrov Z, Ouzounian S, Clavell J, Kantarjian H, Issa J, Garcia-Manero G. Significant Clinical Activity of the Combination of 5-Azacytidine, Valproic Acid and All-Trans Retinoic (ATRA) Acid in Leukemia: Results of a Phase I/II Study. Blood. 108: 160-160. DOI: 10.1182/Blood.V108.11.160.160 |
0.325 |
|
| 2005 |
Garcia-Manero G, Issa JP. Histone deacetylase inhibitors: A review of their clinical status as antineoplastic agents Cancer Investigation. 23: 635-642. PMID 16305991 DOI: 10.1080/07357900500283119 |
0.374 |
|
| 2005 |
Issa JP. DNA methylation in the treatment of hematologic malignancies Clinical Advances in Hematology and Oncology. 3: 684-686. PMID 16224441 |
0.385 |
|
| 2005 |
Toyota M, Issa JPJ. Epigenetic changes in solid and hematopoietic tumors Seminars in Oncology. 32: 521-531. PMID 16210093 DOI: 10.1053/j.seminoncol.2005.07.003 |
0.452 |
|
| 2005 |
Shen L, Kondo Y, Rosner GL, Xiao L, Hernandez NS, Vilaythong J, Houlihan PS, Krouse RS, Prasad AR, Einspahr JG, Buckmeier J, Alberts DS, Hamilton SR, Issa JP. MGMT promoter methylation and field defect in sporadic colorectal cancer. Journal of the National Cancer Institute. 97: 1330-8. PMID 16174854 DOI: 10.1093/Jnci/Dji275 |
0.395 |
|
| 2005 |
Canalli AA, Yang H, Jeha S, Hoshino K, Sanchez-Gonzalez B, Brandt M, Pierce S, Kantarjian H, Issa JP, Garcia-Manero G. Aberrant DNA methylation of a cell cycle regulatory pathway composed of P73, P15 and P57KIP2 is a rare event in children with acute lymphocytic leukemia. Leukemia Research. 29: 881-5. PMID 15978938 DOI: 10.1016/j.leukres.2004.11.023 |
0.337 |
|
| 2005 |
Issa JP, Kantarjian H, Kirkpatrick P. Azacitidine Nature Reviews Drug Discovery. 4. PMID 15962522 DOI: 10.1038/nrd1726 |
0.382 |
|
| 2005 |
Chirieac LR, Shen L, Catalano PJ, Issa JP, Hamilton SR. Phenotype of microsatellite-stable colorectal carcinomas with CpG island methylation. The American Journal of Surgical Pathology. 29: 429-36. PMID 15767794 DOI: 10.1097/01.Pas.0000155144.53047.7D |
0.361 |
|
| 2005 |
Garcia-Manero G, Kantarjian H, Sanchez-Gonzalez B, Yang H, Rosner G, Verstovsek S, Rytting M, Ravandi F, Faderl S, Estrov Z, Cortes J, O’Brien S, Fiorentino J, Issa J. Final Results of a Phase I/II Study of the Combination of the Hypomethylating Agent 5-aza-2′-Deoxycytidine (DAC) and the Histone Deacetylase Inhibitor Valproic Acid (VPA) in Patients with Leukemia. Blood. 106: 408-408. DOI: 10.1182/Blood.V106.11.408.408 |
0.392 |
|
| 2005 |
Oki Y, Jelinek J, Shen L, Issa J. Comprehensive Promoter Methylation Analysis of Genes on 5q31.1 in MDS and AML. Blood. 106: 3443-3443. DOI: 10.1182/Blood.V106.11.3443.3443 |
0.466 |
|
| 2005 |
Oki Y, Kantarjian HM, O’Brien S, Verstovsek S, Gharibyan V, Cortes J, Morris GM, Garcia-Manero G, Issa J. Phase II Study of Decitabine in Combination with Imatinib Mesylate in Patients with Accelerated (AP) or Blastic Phase (BP) of Chronic Myeloid Leukemia (CML). Blood. 106: 1099-1099. DOI: 10.1182/Blood.V106.11.1099.1099 |
0.328 |
|
| 2004 |
Issa JP. CpG island methylator phenotype in cancer Nature Reviews Cancer. 4: 988-993. PMID 15573120 DOI: 10.1038/Nrc1507 |
0.51 |
|
| 2004 |
Rashid A, Issa JPJ. CpG island methylation in gastroenterologic neoplasia: A maturing field Gastroenterology. 127: 1578-1588. PMID 15521024 DOI: 10.1053/j.gastro.2004.09.007 |
0.382 |
|
| 2004 |
Kondo Y, Shen L, Yan PS, Huang TH, Issa JP. Chromatin immunoprecipitation microarrays for identification of genes silenced by histone H3 lysine 9 methylation. Proceedings of the National Academy of Sciences of the United States of America. 101: 7398-403. PMID 15123805 DOI: 10.1073/Pnas.0306641101 |
0.449 |
|
| 2004 |
Youssef EM, Chen XQ, Higuchi E, Kondo Y, Garcia-Manero G, Lotan R, Issa JP. Hypermethylation and silencing of the putative tumor suppressor Tazarotene-induced gene 1 in human cancers. Cancer Research. 64: 2411-7. PMID 15059893 DOI: 10.1158/0008-5472.Can-03-0164 |
0.446 |
|
| 2004 |
Kondo Y, Issa JPJ. Epigenetic changes in colorectal cancer Cancer and Metastasis Reviews. 23: 29-39. PMID 15000147 DOI: 10.1023/A:1025806911782 |
0.464 |
|
| 2004 |
Yang AS, Estécio MR, Doshi K, Kondo Y, Tajara EH, Issa JP. A simple method for estimating global DNA methylation using bisulfite PCR of repetitive DNA elements. Nucleic Acids Research. 32: e38. PMID 14973332 DOI: 10.1093/nar/gnh032 |
0.419 |
|
| 2004 |
Youssef EM, Estecio MRH, Issa JPJ. Methylation and regulation of expression of different retinoic acid receptor β isoforms in human colon cancer Cancer Biology and Therapy. 3: 82-86. PMID 14726683 |
0.369 |
|
| 2004 |
Obata T, Toyota M, Satoh A, Sasaki Y, Ogi K, Akino K, Suzuki H, Murai M, Kikuchi T, Mita H, Itoh F, Issa JP, Tokino T, Imai K. Identification of HRK as a target of epigenetic inactivation in colorectal and gastric cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 9: 6410-8. PMID 14695142 |
0.383 |
|
| 2004 |
Issa JP. Decitabine. Current Opinion in Oncology. 15: 446-51. PMID 14624227 DOI: 10.1097/00001622-200311000-00007 |
0.445 |
|
| 2004 |
Saba H, Rosenfeld C, Issa J, DiPersio J, Raza A, Klimek V, Slack J, Castro Cd, Mettinger K, Kantarjian H. First Report of the Phase III North American Trial of Decitabine in Advanced Myelodysplastic Syndrome (MDS). Blood. 104: 67-67. DOI: 10.1182/Blood.V104.11.67.67 |
0.342 |
|
| 2004 |
Liu TX, Becker M, Hsu K, Jelinek J, Deng M, Bloomfield C, Issa J, Clarke MF, Look AT. Epigenetic Suppression of the CTNNA1 Gene, Encoding the α-Catenin Protein, which Is Located in the 5q31 Critical Deleted Region in Malignant Myeloid Disorders with del(5q). Blood. 104: 203-203. DOI: 10.1182/Blood.V104.11.203.203 |
0.326 |
|
| 2004 |
Jelinek J, Mannari R, Issa J. Identification of 41 Novel Promoter-Associated CpG Islands Methylated in Leukemias. Blood. 104: 1126-1126. DOI: 10.1182/Blood.V104.11.1126.1126 |
0.561 |
|
| 2003 |
Belinsky SA, Klinge DM, Stidley CA, Issa JP, Herman JG, March TH, Baylin SB. Inhibition of DNA methylation and histone deacetylation prevents murine lung cancer. Cancer Research. 63: 7089-93. PMID 14612500 |
0.379 |
|
| 2003 |
Issa JP. Age-related epigenetic changes and the immune system Clinical Immunology. 109: 103-108. PMID 14585281 DOI: 10.1016/S1521-6616(03)00203-1 |
0.467 |
|
| 2003 |
Frazier ML, Xi L, Zong J, Viscofsky N, Rashid A, Wu EF, Lynch PM, Amos CI, Issa JP. Association of the CpG island methylator phenotype with family history of cancer in patients with colorectal cancer. Cancer Research. 63: 4805-8. PMID 12941799 |
0.363 |
|
| 2003 |
Issa JPJ. Methylation and prognosis: Of molecular clocks and hypermethylator phenotypes Clinical Cancer Research. 9: 2879-2881. PMID 12912930 |
0.311 |
|
| 2003 |
Kantarjian HM, O'Brien S, Cortes J, Giles FJ, Faderl S, Issa JP, Garcia-Manero G, Rios MB, Shan J, Andreeff M, Keating M, Talpaz M. Results of decitabine (5-aza-2'deoxycytidine) therapy in 130 patients with chronic myelogenous leukemia. Cancer. 98: 522-8. PMID 12879469 DOI: 10.1002/Cncr.11543 |
0.358 |
|
| 2003 |
Fujii S, Luo RZ, Yuan J, Kadota M, Oshimura M, Dent SR, Kondo Y, Issa JP, Bast RC, Yu Y. Reactivation of the silenced and imprinted alleles of ARHI is associated with increased histone H3 acetylation and decreased histone H3 lysine 9 methylation. Human Molecular Genetics. 12: 1791-800. PMID 12874100 DOI: 10.1093/Hmg/Ddg204 |
0.424 |
|
| 2003 |
Yuan J, Luo RZ, Fujii S, Wang L, Hu W, Andreeff M, Pan Y, Kadota M, Oshimura M, Sahin AA, Issa JP, Bast RC, Yu Y. Aberrant methylation and silencing of ARHI, an imprinted tumor suppressor gene in which the function is lost in breast cancers. Cancer Research. 63: 4174-80. PMID 12874023 |
0.433 |
|
| 2003 |
Li H, Myeroff L, Smiraglia D, Romero MF, Pretlow TP, Kasturi L, Lutterbaugh J, Rerko RM, Casey G, Issa JP, Willis J, Willson JK, Plass C, Markowitz SD. SLC5A8, a sodium transporter, is a tumor suppressor gene silenced by methylation in human colon aberrant crypt foci and cancers. Proceedings of the National Academy of Sciences of the United States of America. 100: 8412-7. PMID 12829793 DOI: 10.1073/Pnas.1430846100 |
0.45 |
|
| 2003 |
Toyota M, Sasaki Y, Satoh A, Ogi K, Kikuchi T, Suzuki H, Mita H, Tanaka N, Itoh F, Issa JP, Jair KW, Schuebel KE, Imai K, Tokino T. Epigenetic inactivation of CHFR in human tumors. Proceedings of the National Academy of Sciences of the United States of America. 100: 7818-23. PMID 12810945 DOI: 10.1073/pnas.1337066100 |
0.448 |
|
| 2003 |
Kondo Y, Issa JPJ. Enrichment for histone H3 lysine 9 methylation at Alu repeats in human cells Journal of Biological Chemistry. 278: 27658-27662. PMID 12724318 DOI: 10.1074/jbc.M304072200 |
0.343 |
|
| 2003 |
Yu Y, Fujii S, Yuan J, Luo RZ, Wang L, Bao J, Kadota M, Oshimura M, Dent SR, Issa JP, Bast RC. Epigenetic regulation of ARHI in breast and ovarian cancer cells. Annals of the New York Academy of Sciences. 983: 268-77. PMID 12724231 DOI: 10.1111/J.1749-6632.2003.Tb05981.X |
0.47 |
|
| 2003 |
Shen L, Kondo Y, Hamilton SR, Rashid A, Issa JP. P14 methylation in human colon cancer is associated with microsatellite instability and wild-type p53. Gastroenterology. 124: 626-33. PMID 12612901 DOI: 10.1053/gast.2003.50102 |
0.333 |
|
| 2003 |
Shen L, Toyota M, Kondo Y, Obata T, Daniel S, Pierce S, Imai K, Kantarjian HM, Issa JP, Garcia-Manero G. Aberrant DNA methylation of p57KIP2 identifies a cell-cycle regulatory pathway with prognostic impact in adult acute lymphocytic leukemia. Blood. 101: 4131-6. PMID 12586619 DOI: 10.1182/blood-2002-08-2466 |
0.45 |
|
| 2003 |
Chan AO, Kim SG, Bedeir A, Issa JP, Hamilton SR, Rashid A. CpG island methylation in carcinoid and pancreatic endocrine tumors. Oncogene. 22: 924-34. PMID 12584572 DOI: 10.1038/sj.onc.1206123 |
0.303 |
|
| 2003 |
Garcia-Manero G, Jeha S, Daniel J, Williamson J, Albitar M, Kantarjian HM, Issa JP. Aberrant DNA methylation in pediatric patients with acute lymphocytic leukemia. Cancer. 97: 695-702. PMID 12548613 DOI: 10.1002/cncr.11090 |
0.397 |
|
| 2003 |
Kondo Y, Shen L, Issa JPJ. Critical role of histone methylation in tumor suppressor gene silencing in colorectal cancer Molecular and Cellular Biology. 23: 206-215. PMID 12482974 DOI: 10.1128/MCB.23.1.206-215.2003 |
0.495 |
|
| 2002 |
Shen L, Kondo Y, Issa J, Garcia-Manero G. Lack of p21CIP1 DNA methylation in acute lymphocytic leukemia Blood. 100: 3432-3433. PMID 12412576 DOI: 10.1182/Blood-2002-07-1990 |
0.439 |
|
| 2002 |
Issa JP. Epigenetic variation and human disease Journal of Nutrition. 132. PMID 12163698 DOI: 10.1093/Jn/132.8.2388S |
0.445 |
|
| 2002 |
Garcia-Manero G, Daniel J, Smith TL, Kornblau SM, Lee MS, Kantarjian HM, Issa JP. DNA methylation of multiple promoter-associated CpG islands in adult acute lymphocytic leukemia. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 8: 2217-24. PMID 12114423 |
0.413 |
|
| 2002 |
Garcia-Manero G, Bueso-Ramos C, Daniel J, Williamson J, Kantarjian HM, Issa JP. DNA methylation patterns at relapse in adult acute lymphocytic leukemia. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 8: 1897-903. PMID 12060634 |
0.427 |
|
| 2002 |
Soria JC, Lee HY, Lee JI, Wang L, Issa JP, Kemp BL, Liu DD, Kurie JM, Mao L, Khuri FR. Lack of PTEN expression in non-small cell lung cancer could be related to promoter methylation. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 8: 1178-84. PMID 12006535 |
0.32 |
|
| 2002 |
Chan AO, Broaddus RR, Houlihan PS, Issa JP, Hamilton SR, Rashid A. CpG island methylation in aberrant crypt foci of the colorectum. The American Journal of Pathology. 160: 1823-30. PMID 12000733 DOI: 10.1016/S0002-9440(10)61128-5 |
0.391 |
|
| 2002 |
Kikuchi T, Toyota M, Itoh F, Suzuki H, Obata T, Yamamoto H, Kakiuchi H, Kusano M, Issa JP, Tokino T, Imai K. Inactivation of p57KIP2 by regional promoter hypermethylation and histone deacetylation in human tumors. Oncogene. 21: 2741-9. PMID 11965547 DOI: 10.1038/sj.onc.1205376 |
0.455 |
|
| 2002 |
Toyota M, Issa JPJ. Methylated CpG island amplification for methylation analysis and cloning differentially methylated sequences Methods in Molecular Biology (Clifton, N.J.). 200: 101-110. PMID 11951646 |
0.346 |
|
| 2002 |
Moinova HR, Chen WD, Shen L, Smiraglia D, Olechnowicz J, Ravi L, Kasturi L, Myeroff L, Plass C, Parsons R, Minna J, Willson JK, Green SB, Issa JP, Markowitz SD. HLTF gene silencing in human colon cancer. Proceedings of the National Academy of Sciences of the United States of America. 99: 4562-7. PMID 11904375 DOI: 10.1073/Pnas.062459899 |
0.422 |
|
| 2002 |
Chan AO, Issa JP, Morris JS, Hamilton SR, Rashid A. Concordant CpG island methylation in hyperplastic polyposis. The American Journal of Pathology. 160: 529-36. PMID 11839573 DOI: 10.1016/S0002-9440(10)64872-9 |
0.35 |
|
| 2001 |
Santini V, Kantarjian HM, Issa JP. Changes in DNA methylation in neoplasia: Pathophysiology and therapeutic implications Annals of Internal Medicine. 134: 573-586. PMID 11281740 DOI: 10.7326/0003-4819-134-7-200104030-00011 |
0.544 |
|
| 2000 |
Issa JP. The epigenetics of colorectal cancer Annals of the New York Academy of Sciences. 910: 140-155. PMID 10911911 DOI: 10.1111/J.1749-6632.2000.Tb06706.X |
0.521 |
|
| 1999 |
Issa JP. Aging, DNA methylation and cancer Critical Reviews in Oncology/Hematology. 32: 31-43. PMID 10586353 DOI: 10.1016/S1040-8428(99)00019-0 |
0.549 |
|
| 1998 |
Lengauer C, Issa JP. The role of epigenetics in cancer Molecular Medicine Today. 4: 102-103. PMID 9575489 DOI: 10.1016/S1357-4310(98)01220-9 |
0.504 |
|
| 1995 |
Wales MM, Biel MA, el Deiry W, Nelkin BD, Issa JP, Cavenee WK, Kuerbitz SJ, Baylin SB. p53 activates expression of HIC-1, a new candidate tumour suppressor gene on 17p13.3. Nature Medicine. 1: 570-7. PMID 7585125 DOI: 10.1038/Nm0695-570 |
0.414 |
|
| Low-probability matches (unlikely to be authored by this person) |
| 2005 |
Issa JP, Gharibyan V, Cortes J, Jelinek J, Morris G, Verstovsek S, Talpaz M, Garcia-Manero G, Kantarjian HM. Phase II study of low-dose decitabine in patients with chronic myelogenous leukemia resistant to imatinib mesylate. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 23: 3948-56. PMID 15883410 DOI: 10.1200/JCO.2005.11.981 |
0.3 |
|
| 2009 |
Cleyrat C, Jelinek J, Girodon F, Boissinot M, Ponge T, Harousseau J, Issa J, Hermouet S. Polycythemia Vera with Multiple Clones Carrying Different Mutations (L611V, V617F, L611V/V617F) in Exon 14 of JAK2. Blood. 114: 3908-3908. DOI: 10.1182/Blood.V114.22.3908.3908 |
0.299 |
|
| 2006 |
Jabbour E, O’Brien S, Ravandi-Kashani F, Cortes J, Borthakur G, Verstovsek S, Garcia-Manero G, Giles F, Zanoria L, Davisson J, Issa J, Kantarjian HM. Decitabine Induces High Response Rates in Patients with Chronic Myelomonocytic Leukemia (CMML). Blood. 108: 2655-2655. DOI: 10.1182/Blood.V108.11.2655.2655 |
0.299 |
|
| 2019 |
Deliard S, Okamoto Y, Madzo J, Pandey S, Jelinek J, Issa J. Abstract 4331: Potential role of the splicing factor SF3B1 in epigenetic regulation and activation of p53 signaling Cancer Research. DOI: 10.1158/1538-7445.Sabcs18-4331 |
0.298 |
|
| 2020 |
Leclerc D, Jelinek J, Christensen KE, Issa JJ, Rozen R. High folic acid intake increases methylation-dependent expression of Lsr and dysregulates hepatic cholesterol homeostasis. The Journal of Nutritional Biochemistry. 108554. PMID 33220403 DOI: 10.1016/j.jnutbio.2020.108554 |
0.298 |
|
| 2007 |
Shen L, Toyota M, Kondo Y, Lin E, Zhang L, Guo Y, Hernandez NS, Chen X, Ahmed S, Konishi K, Hamilton SR, Issa JP. Integrated genetic and epigenetic analysis identifies three different subclasses of colon cancer. Proceedings of the National Academy of Sciences of the United States of America. 104: 18654-9. PMID 18003927 DOI: 10.1073/pnas.0704652104 |
0.297 |
|
| 2009 |
Kim MJ, White-Cross JA, Shen L, Issa JP, Rashid A. Hypomethylation of long interspersed nuclear element-1 in hepatocellular carcinomas. Modern Pathology : An Official Journal of the United States and Canadian Academy of Pathology, Inc. 22: 442-9. PMID 19136926 DOI: 10.1038/modpathol.2008.203 |
0.296 |
|
| 2014 |
Stewart DJ, Nunez MI, Jelinek J, Hong D, Gupta S, Aldaz M, Issa JP, Kurzrock R, Wistuba II. Impact of decitabine on immunohistochemistry expression of the putative tumor suppressor genes FHIT, WWOX, FUS1 and PTEN in clinical tumor samples. Clinical Epigenetics. 6: 13. PMID 25024751 DOI: 10.1186/1868-7083-6-13 |
0.295 |
|
| 2013 |
Roboz GJ, Issa J, Rizzieri D, Stock W, O'Connell C, Yee K, Tibes R, Griffiths EA, Walsh K, Feldman EJ, Ritchie E, Rao AV, Larson RA, Garcia-Manero G, Ravandi F, et al. DNA Demethylation Activity Over Time and Safety Of 3 Different Dose-Escalation Regimens Of SGI-110, a Novel Subcutaneous (SQ) Hypomethylating Agent (HMA), In The Treatment Of Relapsed/Refractory Patients With MDS and AML Blood. 122: 1548-1548. DOI: 10.1182/Blood.V122.21.1548.1548 |
0.292 |
|
| 2015 |
Issa JP, Roboz G, Rizzieri D, Jabbour E, Stock W, O'Connell C, Yee K, Tibes R, Griffiths EA, Walsh K, Daver N, Chung W, Naim S, Taverna P, Oganesian A, et al. Safety and tolerability of guadecitabine (SGI-110) in patients with myelodysplastic syndrome and acute myeloid leukaemia: a multicentre, randomised, dose-escalation phase 1 study. The Lancet. Oncology. 16: 1099-110. PMID 26296954 DOI: 10.1016/S1470-2045(15)00038-8 |
0.292 |
|
| 2024 |
Zhang H, Huang C, Gordon J, Yu S, Morton G, Childers W, Abou-Gharbia M, Zhang Y, Jelinek J, Issa JJ. MC180295 is a highly potent and selective CDK9 inhibitor with preclinical in vitro and in vivo efficacy in cancer. Clinical Epigenetics. 16: 3. PMID 38172923 DOI: 10.1186/s13148-023-01617-3 |
0.291 |
|
| 2007 |
Kantarjian H, Garcia-Manero G, O’Brien S, Estrov Z, Ravandi F, Cortes J, Shan J, Davisson J, Issa J. Survival and Efficacy of Decitabine in Myelodysplastic Syndromes (MDS), Analysis of the 5-Day IV Dosing Regimen. Blood. 110: 115-115. DOI: 10.1182/Blood.V110.11.115.115 |
0.284 |
|
| 2008 |
Suehiro Y, Wong CW, Chirieac LR, Kondo Y, Shen L, Webb CR, Chan YW, Chan AS, Chan TL, Wu TT, Rashid A, Hamanaka Y, Hinoda Y, Shannon RL, Wang X, ... ... Issa JP, et al. Epigenetic-genetic interactions in the APC/WNT, RAS/RAF, and P53 pathways in colorectal carcinoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 14: 2560-9. PMID 18451217 DOI: 10.1158/1078-0432.Ccr-07-1802 |
0.284 |
|
| 2007 |
Silva LDP, Lima Md, Kantarjian H, Champlin R, Faderl S, Giralt S, Kebriaei P, Davisson J, Estey E, Garcia-Manero G, Issa J, Ravandi F. Outcome of Allogeneic Stem Cell Transplantation after Hypomethylating Therapy with 2′-Deoxy-5 Azacytidine for Patients with Myelodysplastic Syndrome. Blood. 110: 1468-1468. DOI: 10.1182/Blood.V110.11.1468.1468 |
0.283 |
|
| 2006 |
Jabbour E, Kantarjian HM, Cortes J, Wierda WG, Ferrajoli A, Faderl S, O’Brien S, Ravandi-Kashani F, Verstovsek S, Garcia-Manero G, Davisson J, Giles F, Shan J, Issa J. Survival Benefit with Decitabine Compared to Historical Experience with Intensive Chemotherapy in Patients with Higher Risk Myelodysplastic Syndrome (MDS). Blood. 108: 2652-2652. DOI: 10.1182/Blood.V108.11.2652.2652 |
0.282 |
|
| 2002 |
Shen L, Ahuja N, Shen Y, Habib NA, Toyota M, Rashid A, Issa JP. DNA methylation and environmental exposures in human hepatocellular carcinoma. Journal of the National Cancer Institute. 94: 755-61. PMID 12011226 DOI: 10.1093/jnci/94.10.755 |
0.282 |
|
| 2008 |
Ravandi F, Issa J, Garcia-Manero G, O’Brien S, Pierce S, Shan J, Verstovsek S, Faderl S, Cortes J, Kantarjian H. Hypomethylating Therapy in Patients with AML and High-Risk MDS and Chromosome 5 and 7 Abnormalities Is Associated with An Improved Outcome Compared to Conventional Chemotherapy Blood. 112: 2955-2955. DOI: 10.1182/Blood.V112.11.2955.2955 |
0.281 |
|
| 2006 |
Borthakur G, Ravandi-Kashani F, Cortes J, Jabbour E, Faderl S, O’Brien S, Verstovsek S, Garcia-Manero G, Newman BA, Giles F, Issa J, Kantarjian HM. Decitabine Induces Responses in Patients with Myelodysplastic Syndrome (MDS) after Failure of Azacitidine Therapy. Blood. 108: 518-518. DOI: 10.1182/Blood.V108.11.518.518 |
0.281 |
|
| 2011 |
Watanabe Y, Castoro RJ, Kim HS, North B, Oikawa R, Hiraishi T, Ahmed SS, Chung W, Cho MY, Toyota M, Itoh F, Estecio MR, Shen L, Jelinek J, Issa JP. Frequent alteration of MLL3 frameshift mutations in microsatellite deficient colorectal cancer. Plos One. 6: e23320. PMID 21853109 DOI: 10.1371/journal.pone.0023320 |
0.28 |
|
| 2016 |
Daver N, Kantarjian HM, Roboz GJ, Kropf PL, Yee KWL, O'Connell CL, Griffiths EA, Jabbour EJ, Stock W, Walsh KJ, Rizzieri DA, Berdeja JG, Su XY, Azab M, Issa J. Long Term Survival and Clinical Complete Responses of Various Prognostic Subgroups in 103 Relapsed/Refractory Acute Myeloid Leukemia (r/r AML) Patients Treated with Guadecitabine (SGI-110) in Phase 2 Studies Blood. 128: 904-904. DOI: 10.1182/Blood.V128.22.904.904 |
0.279 |
|
| 2004 |
Maruya S, Issa JP, Weber RS, Rosenthal DI, Haviland JC, Lotan R, El-Naggar AK. Differential methylation status of tumor-associated genes in head and neck squamous carcinoma: incidence and potential implications. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 10: 3825-30. PMID 15173091 DOI: 10.1158/1078-0432.Ccr-03-0370 |
0.278 |
|
| 2015 |
Hossain N, Fung H, Issa J, Kropf P. Allogeneic Stem Cell Transplant in AML with Adverse Cytogenetics Clinical Lymphoma, Myeloma & Leukemia. 15. DOI: 10.1016/J.Clml.2015.04.058 |
0.276 |
|
| 2005 |
Garcia-Manero G, Yang H, Sanchez-Gonzalez B, Verstovsek S, Ferrajoli A, Keating M, Andreeff M, O’Brien S, Cortes J, Wierda W, Faderl S, Koller C, Davis J, Morris G, Issa J, et al. Final Results of a Phase I Study of the Histone Deacetylase Inhibitor Vorinostat (Suberoyanilide Hydroxamic Acid, SAHA), in Patients with Leukemia and Myelodysplastic Syndrome. Blood. 106: 2801-2801. DOI: 10.1182/Blood.V106.11.2801.2801 |
0.274 |
|
| 2012 |
Kantarjian HM, Roboz GJ, Rizzieri DA, Stock W, O'Connell CL, Griffiths EA, Yee K, Tibes R, Garcia-Manero G, Ravandi F, Walsh K, Feldman E, Ritchie E, Rao A, Decastro C, ... ... Issa J, et al. Results From the Dose Escalation Phase of a Randomized Phase 1–2 First-in-Human (FIH) Study of SGI-110, a Novel Low Volume Stable Subcutaneous (SQ) Second Generation Hypomethylating Agent (HMA) in Patients with Relapsed/Refractory MDS and AML Blood. 120: 414-414. DOI: 10.1182/Blood.V120.21.414.414 |
0.274 |
|
| 2007 |
Lee S, Jeong J, Majewski T, Scherer SE, Kim MS, Tuziak T, Tang KS, Baggerly K, Grossman HB, Zhou JH, Shen L, Bondaruk J, Ahmed SS, Samanta S, Spiess P, ... ... Issa JP, et al. Forerunner genes contiguous to RB1 contribute to the development of in situ neoplasia. Proceedings of the National Academy of Sciences of the United States of America. 104: 13732-7. PMID 17702869 DOI: 10.1073/Pnas.0701771104 |
0.274 |
|
| 2015 |
Chung W, Taverna P, Lyons J, Hao Y, Azab M, Kantarjian H, Kropf P, Issa J. Abstract 2952: Determinants of hypomethylation and clinical responses in relapsed/refractory AML patients treated with SGI-110, a novel hypomethylating agent in a phase 1/2 study Cancer Research. 75: 2952-2952. DOI: 10.1158/1538-7445.Am2015-2952 |
0.271 |
|
| 2010 |
Borthakur G, Huang X, Kantarjian H, Faderl S, Ravandi F, Ferrajoli A, Torma R, Morris G, Berry D, Issa JP. Report of a phase 1/2 study of a combination of azacitidine and cytarabine in acute myelogenous leukemia and high-risk myelodysplastic syndromes. Leukemia & Lymphoma. 51: 73-8. PMID 20017599 DOI: 10.3109/10428190903318329 |
0.271 |
|
| 2007 |
Yanada M, Huang X, O'Brien S, Garcia-Manero G, Ravandi F, Borthakur G, Issa J, Giles F, Kantarjian H, Estey E. Effect of hematologic improvement (HI) on survival in patients (pts) given targeted therapy (TT) as initial treatment of acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (HR-MDS) Journal of Clinical Oncology. 25: 7059-7059. DOI: 10.1200/Jco.2007.25.18_Suppl.7059 |
0.27 |
|
| 2011 |
Spannhoff A, Kim YK, Raynal NJ, Gharibyan V, Su MB, Zhou YY, Li J, Castellano S, Sbardella G, Issa JP, Bedford MT. Histone deacetylase inhibitor activity in royal jelly might facilitate caste switching in bees. Embo Reports. 12: 238-43. PMID 21331099 DOI: 10.1038/Embor.2011.9 |
0.269 |
|
| 2004 |
Kantarjian H, O’Brien S, Giles F, Ravandi-Kashani F, Faderl S, Garcia-Manero G, Davis J, Issa J. Decitabine Low-Dose Schedule (100 mg/m2/Course) in Myelodysplastic Syndrome (MDS). Comparison of 3 Different Dose Schedules. Blood. 106: 2522-2522. DOI: 10.1182/Blood.V106.11.2522.2522 |
0.268 |
|
| 2006 |
Garcia-Manero G, Kantarjian HM, Sanchez-Gonzalez B, Yang H, Rosner G, Verstovsek S, Rytting M, Wierda WG, Ravandi F, Koller C, Xiao L, Faderl S, Estrov Z, Cortes J, O'brien S, ... ... Issa JP, et al. Phase 1/2 study of the combination of 5-aza-2'-deoxycytidine with valproic acid in patients with leukemia. Blood. 108: 3271-9. PMID 16882711 DOI: 10.1182/Blood-2006-03-009142 |
0.267 |
|
| 2018 |
Sun H, He S, Meng L, Wang Y, Zhang H, Liu Y, Wang J, Tao M, Barta SK, Al-Saleem ED, Fung HC, Issa J, Zheng L, Zhang Y. Engineering of CD19-Specific Chimeric Antigen Receptor T Cells with the Integrin CD103 Results in Augmented Therapeutic Efficacy Against Human Lymphoma in a Preclinical Model Blood. 132: 2050-2050. DOI: 10.1182/Blood-2018-99-117354 |
0.265 |
|
| 2006 |
Gollob JA, Sciambi CJ, Peterson BL, Richmond T, Thoreson M, Moran K, Dressman HK, Jelinek J, Issa JP. Phase I trial of sequential low-dose 5-aza-2'-deoxycytidine plus high-dose intravenous bolus interleukin-2 in patients with melanoma or renal cell carcinoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 12: 4619-27. PMID 16899610 DOI: 10.1158/1078-0432.CCR-06-0883 |
0.265 |
|
| 2004 |
Garcia-Manero G, Kantarjian H, Sanchez-Gonzalez B, Faderl S, Verstovsek S, Ravandi F, Ryttling M, Cortes J, Wierda W, Hoshino K, Yang H, Santos-Malave C, Fiorentino J, Jabbour E, Rosner G, ... Issa J, et al. Results of a Phase I/II Study of the Combination of 5-aza-2′-Deoxycytidine (DAC) and Valproic Acid (VPA) in Patients (pts) with Leukemia. Blood. 104: 263-263. DOI: 10.1182/Blood.V104.11.263.263 |
0.264 |
|
| 2005 |
Issa JP. Optimizing therapy with methylation inhibitors in myelodysplastic syndromes: Dose, duration, and patient selection Nature Clinical Practice Oncology. 2. PMID 16341237 DOI: 10.1038/ncponc0355 |
0.264 |
|
| 2006 |
Yu Y, Luo R, Lu Z, Wei Feng W, Badgwell D, Issa JP, Rosen DG, Liu J, Bast RC. Biochemistry and biology of ARHI (DIRAS3), an imprinted tumor suppressor gene whose expression is lost in ovarian and breast cancers. Methods in Enzymology. 407: 455-68. PMID 16757345 DOI: 10.1016/S0076-6879(05)07037-0 |
0.264 |
|
| 2013 |
Pickering CR, Zhang J, Yoo SY, Bengtsson L, Moorthy S, Neskey DM, Zhao M, Ortega Alves MV, Chang K, Drummond J, Cortez E, Xie TX, Zhang D, Chung W, Issa JP, et al. Integrative genomic characterization of oral squamous cell carcinoma identifies frequent somatic drivers. Cancer Discovery. 3: 770-81. PMID 23619168 DOI: 10.1158/2159-8290.Cd-12-0537 |
0.264 |
|
| 2006 |
Oki Y, Jelinek J, Beran M, Verstovsek S, Kantarjian HM, Issa JP. Mutations and promoter methylation status of NPM1 in myeloproliferative disorders. Haematologica. 91: 1147-8. PMID 16870548 |
0.264 |
|
| 2007 |
Kim J, Kim JY, Song KS, Lee YH, Seo JS, Jelinek J, Goldschmidt-Clermont PJ, Issa JP. Epigenetic changes in estrogen receptor beta gene in atherosclerotic cardiovascular tissues and in-vitro vascular senescence. Biochimica Et Biophysica Acta. 1772: 72-80. PMID 17110088 DOI: 10.1016/J.Bbadis.2006.10.004 |
0.264 |
|
| 2005 |
Prchal JT, Chang K, Jelinek J, Guan Y, Gaikwad A, Issa J, Liu E. In Vitro Expansion of Polycythemia Vera Progenitors Favors Expansion of Erythroid Precursors without JAK2 V617F Mutation. Blood. 106: 3506-3506. DOI: 10.1182/Blood.V106.11.3506.3506 |
0.263 |
|
| 2015 |
Kropf P, Barnes G, Tang B, Pathak A, Issa J. Burden of Tyrosine Kinase Inhibitor Failure in Patients with Chronic Myeloid Leukemia Journal of Leukemia. 3: 1-6. DOI: 10.4172/2329-6917.1000170 |
0.261 |
|
| 2014 |
Roboz GJ, Ravandi F, Kropf P, Yee K, O'Connell C, Griffiths E, Stock W, Garcia-Manero G, Jabbour E, Daver N, Pemmaraju N, Issa J, Walsh K, Rizzieri D, Lunin S, et al. 947OCOMPARISON OF EFFICACY AND SAFETY OF 5-DAY AND 10-DAY SCHEDULES OF SGI-110, A NOVEL SUBCUTANEOUS (SC) HYPOMETHYLATING AGENT (HMA), IN THE TREATMENT OF RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA (R/R AML). Annals of Oncology : Official Journal of the European Society For Medical Oncology. 25: iv328. PMID 28171028 DOI: 10.1093/Annonc/Mdu339.4 |
0.261 |
|
| 2019 |
Roboz GJ, Döhner H, Gobbi M, Kropf PL, Mayer J, Krauter J, Robak T, Kantarjian HM, Novak J, Jedrzejczak W, Thomas X, Ojeda-Uribe M, Miyazaki Y, Min YH, Yeh S, ... ... Issa J, et al. Results from a Global Randomized Phase 3 Study of Guadecitabine (G) Vs Treatment Choice (TC) in 815 Patients with Treatment Naïve (TN) AML Unfit for Intensive Chemotherapy (IC) ASTRAL-1 Study: Analysis By Number of Cycles Blood. 134: 2591-2591. DOI: 10.1182/Blood-2019-127253 |
0.26 |
|
| 2019 |
Issa J, Gobbi M, Kropf PL, Fenaux P, Roboz GJ, Mayer J, Krauter J, Robak T, Kantarjian HM, Novak J, Jedrzejczak WW, Thomas X, Ojeda-Uribe M, Miyazaki Y, Min YH, et al. Progression Free Survival (PFS), and Event Free Survival (EFS) from a Global Randomized Phase 3 Study of Guadecitabine (G) Vs Treatment Choice (TC) in 815 Patients with Treatment Naïve (TN) AML Unfit for Intensive Chemotherapy (IC): ASTRAL-1 Study Blood. 134: 4235-4235. DOI: 10.1182/Blood-2019-129614 |
0.26 |
|
| 2009 |
Watanabe Y, Kim HS, Castoro RJ, Chung W, Estecio MR, Kondo K, Guo Y, Ahmed SS, Toyota M, Itoh F, Suk KT, Cho MY, Shen L, Jelinek J, Issa JP. Sensitive and specific detection of early gastric cancer with DNA methylation analysis of gastric washes. Gastroenterology. 136: 2149-58. PMID 19375421 DOI: 10.1053/j.gastro.2009.02.085 |
0.254 |
|
| 2015 |
Roboz G, Kantarjian H, Kropf P, Richie E, Jain N, Griffiths E, Podoltsev NA, Walsh K, O'Connell C, Stock W, Rizzieri D, Tibes R, Rosenblat T, Chung W, Taverna P, ... ... Issa J, et al. Abstract CT321: First results of a 10-day regimen of SGI-110 (guadecitabine), a second generation hypomethylating agent (HMA) in previously untreated elderly AML who are not candidates for intensive chemotherapy Clinical Trials. 75. DOI: 10.1158/1538-7445.Am2015-Ct321 |
0.254 |
|
| 2007 |
Oki Y, Jelinek J, Shen L, Kantarjian HM, Issa JP. Induction of hypomethylation and molecular response after decitabine therapy in patients with chronic myelomonocytic leukemia. Blood. 111: 2382-4. PMID 18055864 DOI: 10.1182/blood-2007-07-103960 |
0.253 |
|
| 2008 |
Kirschbaum M, Gojo I, Goldberg SL, Kujawski L, Atallah E, Marks P, Vargas JG, Rizvi S, Gravio DD, Ahern J, Issa J. Phase I Study of Vorinostat in Combination with Decitabine in Patients with Relapsed or Newly Diagnosed Acute Myelogenous Leukemia or Myelodysplastic Syndrome Blood. 112: 3651-3651. DOI: 10.1182/Blood.V112.11.3651.3651 |
0.252 |
|
| 2015 |
Kantarjian HM, Roboz GJ, Kropf PL, Yee KW, O'Connell CL, Tibes R, Walsh KJ, Podeltsev NA, Griffiths EA, Jabbour E, Garcia-Manero G, Rizzieri DA, Stock W, Savona MR, Rosenblat TL, ... ... Issa J, et al. Comparison of Efficacy and Safety Results in 103 Treatment-Naïve Acute Myeloid Leukemia (TN-AML) Patients Not Candidates for Intensive Chemotherapy Using 5-Day and 10-Day Regimens of Guadecitabine (SGI-110), a Novel Hypomethylating Agent (HMA) Blood. 126: 458-458. DOI: 10.1182/Blood.V126.23.458.458 |
0.251 |
|
| 2018 |
Garcia-Manero G, Ritchie EK, Walsh KJ, Savona MR, Kantarjian HM, Kropf PL, O'Connell CL, Tibes R, Daver NG, Jabbour EJ, Lunin SD, Rosenblat TL, Yee KW, Stock W, Griffiths EA, ... ... Issa J, et al. Long Term Results of a Randomized Phase 2 Dose-Response Study of Guadecitabine, a Novel Subcutaneous (SC) Hypomethylating Agent (HMA), in 102 Patients with Intermediate or High Risk Myelodysplastic Syndromes (MDS) or Chronic Myelomonocytic Leukemia (CMML) Blood. 132: 231-231. DOI: 10.1182/Blood-2018-99-110465 |
0.251 |
|
| 2001 |
Martinez ME, Einspahr J, Issa J, Giuliano A, Kadlubar F, Alberts DS. Effect of 677 C to T mutations in the methylenetetrahydrofolate reductase gene, folate intake and plasma homocysteine on adenoma recurrence Nature Genetics. 27: 72-72. DOI: 10.1038/87202 |
0.249 |
|
| 2004 |
Youssef EM, Issa JP, Lotan R. Regulation of RARbeta1 expression in head and neck cancer cells by cell density-dependent chromatin remodeling. Cancer Biology & Therapy. 3: 1002-6. PMID 15467435 DOI: 10.4161/Cbt.3.10.1139 |
0.248 |
|
| 2007 |
Tabe Y, Konopleva M, Kondo Y, Contractor R, Tsao T, Konoplev S, Shi Y, Ling X, Watt JC, Tsutsumi-Ishii Y, Ohsaka A, Nagaoka I, Issa JP, Kogan SC, Andreeff M. PPARgamma-active triterpenoid CDDO enhances ATRA-induced differentiation in APL. Cancer Biology & Therapy. 6: 1967-77. PMID 18075297 DOI: 10.4161/Cbt.6.12.4982 |
0.247 |
|
| 2006 |
Issa J, Kantarjian HM, Saba HI. Cytogenetic responses to the hypomethylating agent, decitabine (DAC), in a phase III trial of DAC vs supportive care (SC) in patients (pts) with myelodysplastic syndromes (MDS) Journal of Clinical Oncology. 24: 6501-6501. DOI: 10.1200/Jco.2006.24.18_Suppl.6501 |
0.246 |
|
| 2007 |
Issa J, Saba HI, Garcia-Manero G, Shan J, Kantarjian HM. Decitabine in older patients with acute myelogenous leukemia (AML) Journal of Clinical Oncology. 25: 7021-7021. DOI: 10.1200/Jco.2007.25.18_Suppl.7021 |
0.244 |
|
| 2017 |
Issa JJ. Introduction: Cancer as an Epigenetic Disease. Cancer Journal (Sudbury, Mass.). 23: 255-256. PMID 28926424 DOI: 10.1097/PPO.0000000000000285 |
0.243 |
|
| 2005 |
Issa JPJ, Byrd JC. Decitabine in chronic leukemias Seminars in Hematology. 42. PMID 16015505 DOI: 10.1053/j.seminhematol.2005.05.005 |
0.243 |
|
| 2015 |
Kropf P, Barnes G, Tang B, Pathak A, Issa J. Healthcare Utilization and Costs Associated With Multiple Switching of Tyrosine Kinase Inhibitor therapy In Patients With Chronic Myeloid Leukemia Value in Health. 18. DOI: 10.1016/J.Jval.2015.03.1155 |
0.242 |
|
| 2017 |
Kantarjian HM, Roboz GJ, Kropf PL, Jabbour EJ, Yee KWL, O'Connell CL, Garcia-Manero G, Griffiths EA, Walsh KJ, Stock W, Tibes R, Podoltsev NA, Hao Y, Ahanonu V, Azab M, ... Issa J, et al. Predictors of Response and Survival in 206 AML Patients Treated with Guadecitabine in a Phase 2 Study Blood. 130: 3854-3854. DOI: 10.1182/Blood.V130.Suppl_1.3854.3854 |
0.241 |
|
| 2017 |
Herceg Z, Ghantous A, Wild CP, Sklias A, Casati L, Duthie SJ, Fry R, Issa JP, Kellermayer R, Koturbash I, Kondo Y, Lepeule J, Lima SCS, Marsit CJ, Rakyan V, et al. Roadmap for Investigating Epigenome Deregulation and Environmental Origins of Cancer. International Journal of Cancer. PMID 28836271 DOI: 10.1002/Ijc.31014 |
0.24 |
|
| 2014 |
Tahara T, Yamamoto E, Suzuki H, Maruyama R, Chung W, Garriga J, Jelinek J, Yamano HO, Sugai T, An B, Shureiqi I, Toyota M, Kondo Y, Estécio MR, Issa JP. Fusobacterium in colonic flora and molecular features of colorectal carcinoma. Cancer Research. 74: 1311-8. PMID 24385213 DOI: 10.1158/0008-5472.CAN-13-1865 |
0.239 |
|
| 2019 |
Griffiths EA, Kantarjian HM, O'Connell CL, Yee KWL, Stock W, Daver NG, Jabbour E, Ritchie EK, Issa J, Walsh KJ, Rizzieri DA, Lunin SD, Su XY, Azab M, Roboz GJ. Durable Remission and Long-Term Survival in Relapsed/Refractory (r/r) AML Patients Treated with Guadecitabine, Median Survival Not Reached for Responders after Long Term Follow up from Phase 2 Study of 103 Patients Blood. 134: 1319-1319. DOI: 10.1182/Blood-2019-131394 |
0.238 |
|
| 2019 |
Bell CG, Lowe R, Adams PD, Baccarelli AA, Beck S, Bell JT, Christensen BC, Gladyshev VN, Heijmans BT, Horvath S, Ideker T, Issa JJ, Kelsey KT, Marioni RE, Reik W, et al. DNA methylation aging clocks: challenges and recommendations. Genome Biology. 20: 249. PMID 31767039 DOI: 10.1186/S13059-019-1824-Y |
0.237 |
|
| 2007 |
Soriano AO, Yang H, Faderl S, Estrov Z, Giles F, Ravandi F, Cortes J, Wierda WG, Ouzounian S, Quezada A, Pierce S, Estey EH, Issa JP, Kantarjian HM, Garcia-Manero G. Safety and clinical activity of the combination of 5-azacytidine, valproic acid, and all-trans retinoic acid in acute myeloid leukemia and myelodysplastic syndrome. Blood. 110: 2302-8. PMID 17596541 DOI: 10.1182/blood-2007-03-078576 |
0.236 |
|
| 2013 |
Natsume A, Ito M, Katsushima K, Ohka F, Hatanaka A, Shinjo K, Sato S, Takahashi S, Ishikawa Y, Takeuchi I, Shimogawa H, Uesugi M, Okano H, Kim SU, Wakabayashi T, ... Issa JP, et al. Chromatin regulator PRC2 is a key regulator of epigenetic plasticity in glioblastoma. Cancer Research. 73: 4559-70. PMID 23720055 DOI: 10.1158/0008-5472.Can-13-0109 |
0.236 |
|
| 2019 |
Savona MR, Kantarjian HM, Roboz GJ, O'Connell CL, Walsh KJ, Tibes R, Yee KW, Stock W, Griffiths EA, Jabbour E, Lunin SD, Rosenblat TL, Podoltsev NA, Issa J, Su XY, et al. Landmark Response and Survival Analyses from 102 MDS and CMML Patients Treated with Guadecitabine in a Phase 2 Study Showing That Maximum Response and Survival Is Best Achieved with Adequate Treatment Duration Blood. 134: 2957-2957. DOI: 10.1182/Blood-2019-129962 |
0.236 |
|
| 2019 |
Yee KW, Roboz GJ, O'Connell CL, Griffiths EA, Tibes R, Walsh KJ, Stock W, Garcia-Manero G, Savona MR, Ravandi F, Daver NG, Jabbour E, Rosenblat TL, Issa J, Su XY, et al. Landmark Response and Survival Analyses from 206 AML Patients Treated with Guadecitabine in a Phase 2 Study Demonstrate the Importance of Adequate Treatment Duration to Maximize Response and Survival Benefit. Survival Benefit Not Restricted to Patients with Objective Response Blood. 134: 3846-3846. DOI: 10.1182/Blood-2019-129845 |
0.231 |
|
| 2007 |
Shen L, Guo Y, Chen X, Ahmed S, Issa JP. Optimizing annealing temperature overcomes bias in bisulfite PCR methylation analysis. Biotechniques. 42: 48, 50, 52 passim. PMID 17269485 DOI: 10.2144/000112312 |
0.229 |
|
| 2009 |
Kantarjian H, O'Brien S, Ravandi F, Borthakur G, Faderl S, Bueso-Ramos C, Abruzzo L, Pierce S, Shan J, Issa JP, Garcia-Manero G. The heterogeneous prognosis of patients with myelodysplastic syndrome and chromosome 5 abnormalities: how does it relate to the original lenalidomide experience in MDS? Cancer. 115: 5202-9. PMID 19691096 DOI: 10.1182/Blood.V112.11.1644.1644 |
0.227 |
|
| 2007 |
Kantarjian HM, Garcia-Manero G, Issa J. Therapy of Myelodysplastic Syndrome Oral History Review. 66. DOI: 10.17925/Ohr.2007.00.01.66 |
0.226 |
|
| 2015 |
Issa JP, Garcia-Manero G, Huang X, Cortes J, Ravandi F, Jabbour E, Borthakur G, Brandt M, Pierce S, Kantarjian HM. Results of phase 2 randomized study of low-dose decitabine with or without valproic acid in patients with myelodysplastic syndrome and acute myelogenous leukemia. Cancer. 121: 556-61. PMID 25336333 DOI: 10.1002/cncr.29085 |
0.226 |
|
| 2008 |
Borthakur G, Ahdab SE, Ravandi F, Faderl S, Ferrajoli A, Newman B, Issa JP, Kantarjian H. Activity of decitabine in patients with myelodysplastic syndrome previously treated with azacitidine. Leukemia & Lymphoma. 49: 690-5. PMID 18398735 DOI: 10.1080/10428190701882146 |
0.225 |
|
| 2019 |
Chung W, Kelly AD, Kropf P, Fung H, Jelinek J, Su XY, Roboz GJ, Kantarjian HM, Azab M, Issa JJ. Genomic and epigenomic predictors of response to guadecitabine in relapsed/refractory acute myelogenous leukemia. Clinical Epigenetics. 11: 106. PMID 31331399 DOI: 10.1186/s13148-019-0704-3 |
0.224 |
|
| 2011 |
Issa JPJ, Garber JE. Time to think outside the (genetic) box Cancer Prevention Research. 4: 6-8. PMID 21205738 DOI: 10.1158/1940-6207.CAPR-10-0348 |
0.222 |
|
| 2005 |
Chan AO, Soliman AS, Zhang Q, Rashid A, Bedeir A, Houlihan PS, Mokhtar N, Al-Masri N, Ozbek U, Yaghan R, Kandilci A, Omar S, Kapran Y, Dizdaroglu F, Bondy ML, ... ... Issa JP, et al. Differing DNA methylation patterns and gene mutation frequencies in colorectal carcinomas from Middle Eastern countries. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 11: 8281-7. PMID 16322286 DOI: 10.1158/1078-0432.Ccr-05-1000 |
0.217 |
|
| 2004 |
Kim SG, Wu TT, Lee JH, Yun YK, Issa JP, Hamilton SR, Rashid A. Comparison of epigenetic and genetic alterations in mucinous cystic neoplasm and serous microcystic adenoma of pancreas. Modern Pathology : An Official Journal of the United States and Canadian Academy of Pathology, Inc. 16: 1086-94. PMID 14614047 DOI: 10.1097/01.MP.0000094088.37888.A6 |
0.217 |
|
| 2007 |
Liu TX, Becker MW, Jelinek J, Wu WS, Deng M, Mikhalkevich N, Hsu K, Bloomfield CD, Stone RM, DeAngelo DJ, Galinsky IA, Issa JP, Clarke MF, Look AT. Chromosome 5q deletion and epigenetic suppression of the gene encoding alpha-catenin (CTNNA1) in myeloid cell transformation. Nature Medicine. 13: 78-83. PMID 17159988 DOI: 10.1038/nm1512 |
0.217 |
|
| 2013 |
Taube JH, Malouf GG, Lu E, Sphyris N, Vijay V, Ramachandran PP, Ueno KR, Gaur S, Nicoloso MS, Rossi S, Herschkowitz JI, Rosen JM, Issa JP, Calin GA, Chang JT, et al. Epigenetic silencing of microRNA-203 is required for EMT and cancer stem cell properties. Scientific Reports. 3: 2687. PMID 24045437 DOI: 10.1038/Srep02687 |
0.217 |
|
| 2012 |
Beck S, Bernstein BE, Campbell RM, Costello JF, Dhanak D, Ecker JR, Greally JM, Issa JP, Laird PW, Polyak K, Tycko B, Jones PA. A blueprint for an international cancer epigenome consortium. A report from the AACR Cancer Epigenome Task Force. Cancer Research. 72: 6319-24. PMID 23188507 DOI: 10.1158/0008-5472.Can-12-3658 |
0.21 |
|
| 2014 |
Xu Y, Zheng X, Yuan Y, Estecio MR, Issa JP, Qiu P, Ji Y, Liang S. BM-SNP: A Bayesian Model for SNP Calling Using High Throughput Sequencing Data. Ieee/Acm Transactions On Computational Biology and Bioinformatics / Ieee, Acm. 11: 1038-44. PMID 26357041 DOI: 10.1109/Tcbb.2014.2321407 |
0.207 |
|
| 2017 |
Toth R, Scherer D, Kelemen LE, Risch A, Hazra A, Balavarca Y, Issa JJ, Moreno V, Eeles RA, Ogino S, Wu X, Ye Y, Hung RJ, Goode EL, Ulrich CM. Genetic Variants in Epigenetic Pathways and Risks of Multiple Cancers in the GAME-ON Consortium. Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association For Cancer Research, Cosponsored by the American Society of Preventive Oncology. PMID 28115406 DOI: 10.1158/1055-9965.Epi-16-0728 |
0.207 |
|
| 2008 |
Majewski T, Lee S, Jeong J, Yoon DS, Kram A, Kim MS, Tuziak T, Bondaruk J, Lee S, Park WS, Tang KS, Chung W, Shen L, Ahmed SS, Johnston DA, ... ... Issa JP, et al. Understanding the development of human bladder cancer by using a whole-organ genomic mapping strategy. Laboratory Investigation; a Journal of Technical Methods and Pathology. 88: 694-721. PMID 18458673 DOI: 10.1038/Labinvest.2008.27 |
0.206 |
|
| 2003 |
Yang AS, Estecio MR, Garcia-Manero G, Kantarjian HM, Issa JP. Comment on "Chromosomal instability and tumors promoted by DNA hypomethylation" and "Induction of tumors in nice by genomic hypomethylation". Science (New York, N.Y.). 302: 1153; author reply 1. PMID 14615517 DOI: 10.1126/science.1089523 |
0.201 |
|
| 2008 |
Jabbour E, Issa JP, Garcia-Manero G, Kantarjian H. Evolution of decitabine development: Accomplishments, ongoing investigations, and future strategies Cancer. 112: 2341-2351. PMID 18398832 DOI: 10.1002/cncr.23463 |
0.197 |
|
| 2005 |
Kantarjian HM, Issa JPJ. Decitabine dosing schedules Seminars in Hematology. 42. PMID 16015500 DOI: 10.1053/j.seminhematol.2005.05.006 |
0.191 |
|
| 2009 |
Ware CB, Wang L, Mecham BH, Shen L, Nelson AM, Bar M, Lamba DA, Dauphin DS, Buckingham B, Askari B, Lim R, Tewari M, Gartler SM, Issa JP, Pavlidis P, et al. Histone deacetylase inhibition elicits an evolutionarily conserved self-renewal program in embryonic stem cells. Cell Stem Cell. 4: 359-69. PMID 19341625 DOI: 10.1016/J.Stem.2009.03.001 |
0.187 |
|
| 2007 |
Plimack ER, Stewart DJ, Issa JPJ. Combining epigenetic and cytotoxic therapy in the treatment of solid tumors Journal of Clinical Oncology. 25: 4519-4521. PMID 17925545 DOI: 10.1200/JCO.2007.12.6029 |
0.185 |
|
| 2014 |
Stewart DJ, Nunez MI, Jelinek J, Hong D, Gupta S, Issa JP, Wistuba II, Kurzrock R. Decitabine impact on the endocytosis regulator RhoA, the folate carriers RFC1 and FOLR1, and the glucose transporter GLUT4 in human tumors. Clinical Epigenetics. 6: 2. PMID 24401732 DOI: 10.1186/1868-7083-6-2 |
0.183 |
|
| 2003 |
Cavalli LR, Urban CA, Dai D, de Assis S, Tavares DC, Rone JD, Bleggi-Torres LF, Lima RS, Cavalli IJ, Issa JP, Haddad BR. Genetic and epigenetic alterations in sentinel lymph nodes metastatic lesions compared to their corresponding primary breast tumors. Cancer Genetics and Cytogenetics. 146: 33-40. PMID 14499694 DOI: 10.1016/s0165-4608(03)00123-7 |
0.182 |
|
| 2015 |
Tefferi A, Kantarjian H, Rajkumar SV, Baker LH, Abkowitz JL, Adamson JW, Advani RH, Allison J, Antman KH, Bast RC, Bennett JM, Benz EJ, Berliner N, Bertino J, Bhatia R, ... ... Issa JP, et al. In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs. Mayo Clinic Proceedings. 90: 996-1000. PMID 26211600 DOI: 10.1016/j.mayocp.2015.06.001 |
0.181 |
|
| 2015 |
Laumet G, Garriga J, Chen SR, Zhang Y, Li DP, Smith TM, Dong Y, Jelinek J, Cesaroni M, Issa JP, Pan HL. G9a is essential for epigenetic silencing of K(+) channel genes in acute-to-chronic pain transition. Nature Neuroscience. PMID 26551542 DOI: 10.1038/Nn.4165 |
0.179 |
|
| 2004 |
Issa JP, Garcia-Manero G, Giles FJ, Mannari R, Thomas D, Faderl S, Bayar E, Lyons J, Rosenfeld CS, Cortes J, Kantarjian HM. Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in hematopoietic malignancies. Blood. 103: 1635-40. PMID 14604977 DOI: 10.1182/Blood-2003-03-0687 |
0.178 |
|
| 2015 |
Lowder JN, Taverna P, Issa JP. Will next-generation agents deliver on the promise of epigenetic hypomethylation therapy? Epigenomics. 7: 1083-8. PMID 26541345 DOI: 10.2217/epi.15.66 |
0.178 |
|
| 2004 |
List AF, Vardiman J, Issa JP, DeWitte TM. Myelodysplastic syndromes. Hematology / the Education Program of the American Society of Hematology. American Society of Hematology. Education Program. 297-317. PMID 15561689 DOI: 10.1182/asheducation-2004.1.297 |
0.177 |
|
| 2005 |
Beach R, Chan AO, Wu TT, White JA, Morris JS, Lunagomez S, Broaddus RR, Issa JP, Hamilton SR, Rashid A. BRAF mutations in aberrant crypt foci and hyperplastic polyposis. The American Journal of Pathology. 166: 1069-75. PMID 15793287 DOI: 10.1016/S0002-9440(10)62327-9 |
0.172 |
|
| 2015 |
Kopetz S, Desai J, Chan E, Hecht JR, O'Dwyer PJ, Maru D, Morris V, Janku F, Dasari A, Chung W, Issa JJ, Gibbs P, James B, Powis G, Nolop KB, et al. Phase II Pilot Study of Vemurafenib in Patients With Metastatic BRAF-Mutated Colorectal Cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. PMID 26460303 DOI: 10.1200/JCO.2015.63.2497 |
0.171 |
|
| 2013 |
Issa JP. The myelodysplastic syndrome as a prototypical epigenetic disease. Blood. 121: 3811-7. PMID 23660859 DOI: 10.1182/blood-2013-02-451757 |
0.167 |
|
| 2007 |
Kantarjian HM, O'Brien S, Huang X, Garcia-Manero G, Ravandi F, Cortes J, Shan J, Davisson J, Bueso-Ramos CE, Issa JP. Survival advantage with decitabine versus intensive chemotherapy in patients with higher risk myelodysplastic syndrome: comparison with historical experience. Cancer. 109: 1133-7. PMID 17315156 DOI: 10.1002/cncr.22508 |
0.165 |
|
| 2005 |
Issa JPJ, Kantarjian HM. Introduction: emerging role of epigenetic therapy: focus on decitabine Seminars in Hematology. 42. PMID 16015499 |
0.164 |
|
| 2005 |
Issa JPJ, Shen L, Toyota M. CIMP, at last Gastroenterology. 129: 1121-1124. PMID 16143149 DOI: 10.1053/j.gastro.2005.07.040 |
0.16 |
|
| 2008 |
Kantarjian H, O'Brien S, Cortes J, Wierda W, Faderl S, Garcia-Manero G, Issa JP, Estey E, Keating M, Freireich EJ. Therapeutic advances in leukemia and myelodysplastic syndrome over the past 40 years. Cancer. 113: 1933-52. PMID 18798533 DOI: 10.1002/Cncr.23655 |
0.16 |
|
| 2005 |
Akino K, Toyota M, Suzuki H, Mita H, Sasaki Y, Ohe-Toyota M, Issa JP, Hinoda Y, Imai K, Tokino T. The Ras effector RASSF2 is a novel tumor-suppressor gene in human colorectal cancer. Gastroenterology. 129: 156-69. PMID 16012945 DOI: 10.1053/J.GASTRO.2005.03.051 |
0.157 |
|
| 2023 |
Wang Y, He S, Calendo G, Bui T, Tian Y, Lee CY, Zhou Y, Zhao X, Abraham C, Mo W, Chen M, Sanders-Braggs R, Madzo J, Issa JJ, Hexner EO, et al. Tissue-infiltrating Alloreactive T Cells Require Id3 to Deflect PD-1-mediated Immune Suppression during GVHD. Blood. PMID 37871574 DOI: 10.1182/blood.2023021126 |
0.153 |
|
| 2023 |
Fenaux P, Gobbi M, Kropf P, Issa JJ, Roboz GJ, Mayer J, Krauter J, Robak T, Kantarjian HM, Novak J, Jedrzejczak WW, Thomas X, Ojeda-Uribe M, Miyazaki Y, Min YH, et al. Guadecitabine vs treatment choice in newly diagnosed acute myeloid leukemia: a global phase 3 randomized study. Blood Advances. PMID 37276510 DOI: 10.1182/bloodadvances.2023010179 |
0.151 |
|
| 2017 |
Kantarjian HM, Roboz GJ, Kropf PL, Yee KWL, O'Connell CL, Tibes R, Walsh KJ, Podoltsev NA, Griffiths EA, Jabbour E, Garcia-Manero G, Rizzieri D, Stock W, Savona MR, Rosenblat TL, ... ... Issa JJ, et al. Guadecitabine (SGI-110) in treatment-naive patients with acute myeloid leukaemia: phase 2 results from a multicentre, randomised, phase 1/2 trial. The Lancet. Oncology. PMID 28844816 DOI: 10.1016/S1470-2045(17)30576-4 |
0.149 |
|
| 2014 |
Issa JP. Aging and epigenetic drift: a vicious cycle. The Journal of Clinical Investigation. 124: 24-9. PMID 24382386 DOI: 10.1172/JCI69735 |
0.148 |
|
| 2022 |
O'Connell CL, Baer MR, Ørskov AD, Saini SK, Duong VH, Kropf P, Hansen JW, Tsao-Wei D, Jang HS, Emadi A, Holmberg-Thyden S, Cowland J, Brinker BT, Horwood K, Burgos R, ... ... Issa JP, et al. Safety, outcomes and T cell characteristics in patients with relapsed or refractory MDS or CMML treated with atezolizumab in combination with guadecitabine. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 36222848 DOI: 10.1158/1078-0432.CCR-22-1810 |
0.147 |
|
| 2019 |
Pope JL, Yang Y, Newsome RC, Sun W, Sun X, Ukhanova M, Neu J, Issa JP, Mai V, Jobin C. Microbial Colonization Coordinates the Pathogenesis of a Klebsiella pneumoniae Infant Isolate. Scientific Reports. 9: 3380. PMID 30833613 DOI: 10.1038/s41598-019-39887-8 |
0.14 |
|
| 2004 |
Youssef EM, Lotan D, Issa JP, Wakasa K, Fan YH, Mao L, Hassan K, Feng L, Lee JJ, Lippman SM, Hong WK, Lotan R. Hypermethylation of the retinoic acid receptor-beta(2) gene in head and neck carcinogenesis. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 10: 1733-42. PMID 15014026 DOI: 10.1158/1078-0432.Ccr-0989-3 |
0.14 |
|
| 2002 |
Kantarjian HM, Talpaz M, O'Brien S, Smith TL, Giles FJ, Faderl S, Thomas DA, Garcia-Manero G, Issa JP, Andreeff M, Kornblau SM, Koller C, Beran M, Keating M, Rios MB, et al. Imatinib mesylate for Philadelphia chromosome-positive, chronic-phase myeloid leukemia after failure of interferon-alpha: follow-up results. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 8: 2177-87. PMID 12114418 |
0.14 |
|
| 2023 |
Jang HJ, Hostetter G, MacFarlane AW, Madaj Z, Ross EA, Hinoue T, Kulchycki JR, Burgos RS, Tafseer M, Alpaugh RK, Schwebel CL, Kokate R, Geynisman DM, Zibelman MR, Ghatalia P, ... ... Issa JJ, et al. A Phase II Trial of Guadecitabine plus Atezolizumab in Metastatic Urothelial Carcinoma Progressing after Initial Immune Checkpoint Inhibitor Therapy. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 36928921 DOI: 10.1158/1078-0432.CCR-22-3642 |
0.136 |
|
| 2006 |
Kantarjian H, Oki Y, Garcia-Manero G, Huang X, O'Brien S, Cortes J, Faderl S, Bueso-Ramos C, Ravandi F, Estrov Z, Ferrajoli A, Wierda W, Shan J, Davis J, Giles F, ... ... Issa JP, et al. Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia. Blood. 109: 52-7. PMID 16882708 DOI: 10.1182/BLOOD-2006-05-021162 |
0.135 |
|
| 2019 |
Garcia-Manero G, Roboz G, Walsh K, Kantarjian H, Ritchie E, Kropf P, O'Connell C, Tibes R, Lunin S, Rosenblat T, Yee K, Stock W, Griffiths E, Mace J, Podoltsev N, ... ... Issa JJ, et al. Guadecitabine (SGI-110) in patients with intermediate or high-risk myelodysplastic syndromes: phase 2 results from a multicentre, open-label, randomised, phase 1/2 trial. The Lancet. Haematology. PMID 31060979 DOI: 10.1016/S2352-3026(19)30029-8 |
0.135 |
|
| 2007 |
Oki Y, Kantarjian HM, Gharibyan V, Jones D, O'brien S, Verstovsek S, Cortes J, Morris GM, Garcia-Manero G, Issa JP. Phase II study of low-dose decitabine in combination with imatinib mesylate in patients with accelerated or myeloid blastic phase of chronic myelogenous leukemia. Cancer. 109: 899-906. PMID 17236224 DOI: 10.1002/cncr.22470 |
0.134 |
|
| 2013 |
Yamazaki J, Issa JP. Epigenetic aspects of MDS and its molecular targeted therapy. International Journal of Hematology. 97: 175-82. PMID 23054654 DOI: 10.1007/s12185-012-1197-4 |
0.132 |
|
| 2007 |
Yanada M, Huang X, Garcia-Manero G, O'brien S, Ravandi F, Borthakur G, Faderl S, Issa JP, Kantarjian H, Estey E. Effect of haematological improvement on survival in patients given targeted therapy as initial treatment of acute myeloid leukaemia or high-risk myelodysplastic syndrome. British Journal of Haematology. 138: 555-7. PMID 17593249 DOI: 10.1111/j.1365-2141.2007.06670.x |
0.132 |
|
| 2011 |
Fini L, Piazzi G, Daoud Y, Selgrad M, Maegawa S, Garcia M, Fogliano V, Romano M, Graziani G, Vitaglione P, Carmack SW, Gasbarrini A, Genta RM, Issa JP, Boland CR, et al. Chemoprevention of intestinal polyps in ApcMin/+ mice fed with western or balanced diets by drinking annurca apple polyphenol extract. Cancer Prevention Research (Philadelphia, Pa.). 4: 907-15. PMID 21383028 DOI: 10.1158/1940-6207.CAPR-10-0359 |
0.125 |
|
| 2007 |
Kantarjian HM, O'Brien S, Shan J, Aribi A, Garcia-Manero G, Jabbour E, Ravandi F, Cortes J, Davisson J, Issa JP. Update of the decitabine experience in higher risk myelodysplastic syndrome and analysis of prognostic factors associated with outcome. Cancer. 109: 265-73. PMID 17133405 DOI: 10.1002/cncr.22376 |
0.123 |
|
| 2007 |
Temam S, Kawaguchi H, El-Naggar AK, Jelinek J, Tang H, Liu DD, Lang W, Issa JP, Lee JJ, Mao L. Epidermal growth factor receptor copy number alterations correlate with poor clinical outcome in patients with head and neck squamous cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 25: 2164-70. PMID 17538160 DOI: 10.1200/JCO.2006.06.6605 |
0.118 |
|
| 2017 |
Roboz GJ, Kantarjian HM, Yee KWL, Kropf PL, O'Connell CL, Griffiths EA, Stock W, Daver NG, Jabbour E, Ritchie EK, Walsh KJ, Rizzieri D, Lunin SD, Curio T, Chung W, ... ... Issa JJ, et al. Dose, schedule, safety, and efficacy of guadecitabine in relapsed or refractory acute myeloid leukemia. Cancer. PMID 29211308 DOI: 10.1002/cncr.31138 |
0.117 |
|
| 2015 |
Kropf P, Barnes G, Tang B, Pathak A, Issa JJ. Healthcare utilization and costs associated with tyrosine kinase inhibitor switching in patients with chronic myeloid leukemia. Leukemia & Lymphoma. 1-21. PMID 26480922 DOI: 10.3109/10428194.2015.1088654 |
0.113 |
|
| 2017 |
He S, Liu Y, Meng L, Sun H, Wang Y, Ji Y, Purushe J, Chen P, Li C, Madzo J, Issa JP, Soboloff J, Reshef R, Moore B, Gattinoni L, et al. Ezh2 phosphorylation state determines its capacity to maintain CD8+ T memory precursors for antitumor immunity. Nature Communications. 8: 2125. PMID 29242551 DOI: 10.1038/S41467-017-02187-8 |
0.113 |
|
| 2005 |
Jelinek J, Oki Y, Gharibyan V, Bueso-Ramos C, Prchal JT, Verstovsek S, Beran M, Estey E, Kantarjian HM, Issa JPJ. JAK2 mutation 1849G>T is rare in acute leukemias but can be found in CMML, Philadelphia chromosome-negative CML, and megakaryocytic leukemia Blood. 106: 3370-3373. PMID 16037387 DOI: 10.1182/Blood-2005-05-1800 |
0.111 |
|
| 2009 |
Loh ML, Sakai DS, Flotho C, Kang M, Fliegauf M, Archambeault S, Mullighan CG, Chen L, Bergstraesser E, Bueso-Ramos CE, Emanuel PD, Hasle H, Issa JP, van den Heuvel-Eibrink MM, Locatelli F, et al. Mutations in CBL occur frequently in juvenile myelomonocytic leukemia. Blood. 114: 1859-63. PMID 19571318 DOI: 10.1182/Blood-2009-01-198416 |
0.111 |
|
| 2013 |
Lanikova L, Kucerova J, Indrak K, Divoka M, Issa JP, Papayannopoulou T, Prchal JT, Divoky V. β-Thalassemia due to intronic LINE-1 insertion in the β-globin gene (HBB): molecular mechanisms underlying reduced transcript levels of the β-globin(L1) allele. Human Mutation. 34: 1361-5. PMID 23878091 DOI: 10.1002/humu.22383 |
0.109 |
|
| 2012 |
Xu Y, Zheng X, Yuan Y, Estecio MR, Issa JP, Ji Y, Liang S. A Bayesian Model for SNP Discovery Based on Next-Generation Sequencing Data. Ieee International Workshop On Genomic Signal Processing and Statistics : [Proceedings]. Ieee International Workshop On Genomic Signal Processing and Statistics. 2012: 42-45. PMID 26726304 DOI: 10.1109/GENSIPS.2012.6507722 |
0.108 |
|
| 2008 |
Kantarjian H, O'Brien S, Ravandi F, Cortes J, Shan J, Bennett JM, List A, Fenaux P, Sanz G, Issa JP, Freireich EJ, Garcia-Manero G. Proposal for a new risk model in myelodysplastic syndrome that accounts for events not considered in the original International Prognostic Scoring System. Cancer. 113: 1351-61. PMID 18618511 DOI: 10.1002/Cncr.23697 |
0.108 |
|
| 2014 |
Kirschbaum M, Gojo I, Goldberg SL, Bredeson C, Kujawski LA, Yang A, Marks P, Frankel P, Sun X, Tosolini A, Eid JE, Lubiniecki GM, Issa JP. A phase 1 clinical trial of vorinostat in combination with decitabine in patients with acute myeloid leukaemia or myelodysplastic syndrome. British Journal of Haematology. 167: 185-93. PMID 25040094 DOI: 10.1111/bjh.13016 |
0.106 |
|
| 2002 |
Kantarjian HM, O'Brien S, Cortes JE, Smith TL, Rios MB, Shan J, Yang Y, Giles FJ, Thomas DA, Faderl S, Garcia-Manero G, Jeha S, Wierda W, Issa JP, Kornblau SM, et al. Treatment of philadelphia chromosome-positive, accelerated-phase chronic myelogenous leukemia with imatinib mesylate. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 8: 2167-76. PMID 12114417 |
0.101 |
|
| 2003 |
Kim SG, Chan AO, Wu TT, Issa JP, Hamilton SR, Rashid A. Epigenetic and genetic alterations in duodenal carcinomas are distinct from biliary and ampullary carcinomas. Gastroenterology. 124: 1300-10. PMID 12730870 DOI: 10.1016/s0016-5085(03)00278-6 |
0.101 |
|
| 2007 |
Huang X, Biswas S, Oki Y, Issa JP, Berry DA. A parallel phase I/II clinical trial design for combination therapies Biometrics. 63: 429-436+635. PMID 17688495 DOI: 10.1111/j.1541-0420.2006.00685.x |
0.1 |
|
| 2009 |
Ravandi F, Issa JP, Garcia-Manero G, O'Brien S, Pierce S, Shan J, Borthakur G, Verstovsek S, Faderl S, Cortes J, Kantarjian H. Superior outcome with hypomethylating therapy in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome and chromosome 5 and 7 abnormalities. Cancer. 115: 5746-51. PMID 19795507 DOI: 10.1002/cncr.24661 |
0.095 |
|
| 2022 |
Zeidan AM, Fenaux P, Gobbi M, Mayer J, Roboz GJ, Krauter J, Robak T, Kantarjian HM, Novak J, Jedrzejczak WW, Thomas X, Ojeda-Uribe M, Miyazaki Y, Min YH, Yeh SP, ... ... Issa JJ, et al. Prospective Comparison of Outcomes with Azacitidine and Decitabine in AML Patients Ineligible for Intensive Chemotherapy. Blood. PMID 35507690 DOI: 10.1182/blood.2022015832 |
0.093 |
|
| 2007 |
Choi IS, Estecio MR, Nagano Y, Kim do H, White JA, Yao JC, Issa JP, Rashid A. Hypomethylation of LINE-1 and Alu in well-differentiated neuroendocrine tumors (pancreatic endocrine tumors and carcinoid tumors). Modern Pathology : An Official Journal of the United States and Canadian Academy of Pathology, Inc. 20: 802-10. PMID 17483816 DOI: 10.1038/modpathol.3800825 |
0.091 |
|
| 2009 |
Huang X, Ning J, Li Y, Estey E, Issa JP, Berry DA. Using short-term response information to facilitate adaptive randomization for survival clinical trials. Statistics in Medicine. 28: 1680-9. PMID 19326367 DOI: 10.1002/Sim.3578 |
0.089 |
|
| 2010 |
Jabbour E, Garcia-Manero G, Batty N, Shan J, O'Brien S, Cortes J, Ravandi F, Issa JP, Kantarjian H. Outcome of patients with myelodysplastic syndrome after failure of decitabine therapy. Cancer. 116: 3830-4. PMID 20564137 DOI: 10.1002/cncr.25247 |
0.084 |
|
| 2003 |
Yang AS, Issa JP. Mitoxantrone: a hypomethylating agent? Cancer Biology & Therapy. 2: 264-5. PMID 12878862 DOI: 10.4161/cbt.2.3.387 |
0.083 |
|
| 2010 |
Batty GN, Kantarjian H, Issa JP, Jabbour E, Santos FP, McCue D, Garcia-Manero G, Pierce S, O'Brien S, Cortés JE, Ravandi F. Feasibility of therapy with hypomethylating agents in patients with renal insufficiency. Clinical Lymphoma, Myeloma & Leukemia. 10: 205-10. PMID 20511166 DOI: 10.3816/CLML.2010.n.032 |
0.075 |
|
| 2023 |
Kusic DM, Heil J, Zajic S, Brangan A, Dairo O, Heil S, Feigin G, Kacinko S, Buono RJ, Ferraro TN, Rafeq R, Haroz R, Baston K, Bodofsky E, Sabia M, ... ... Issa JJ, et al. Postmortem toxicology findings from the Camden Opioid Research Initiative. Plos One. 18: e0292674. PMID 37910493 DOI: 10.1371/journal.pone.0292674 |
0.066 |
|
| 2019 |
Di Meco A, Jelinek J, Lauretti E, Curtis ME, Issa JJ, Praticό D. Gestational high fat diet protects 3xTg offspring from memory impairments, synaptic dysfunction, and brain pathology. Molecular Psychiatry. PMID 31451749 DOI: 10.1038/s41380-019-0489-y |
0.056 |
|
| 2005 |
Issa JP, Kantarjian HM, Kirkpatrick P. Azacitidine. Nature Reviews. Drug Discovery. 4: 275-6. PMID 15861567 DOI: 10.1038/nrd1698 |
0.046 |
|
| 2010 |
Bryan J, Jabbour E, Prescott H, Garcia-Manero G, Issa JP, Kantarjian H. Current and future management options for myelodysplastic syndromes. Drugs. 70: 1381-94. PMID 20614946 DOI: 10.2165/11537920-000000000-00000 |
0.043 |
|
| 2010 |
Mahlknecht U, Issa JP. Introductory editorial. Clinical Epigenetics. 1: 1. PMID 22704083 DOI: 10.1007/s13148-010-0009-z |
0.011 |
|
| Hide low-probability matches. |